EA010727B1 - Аминогетероарильные соединения в качестве ингибиторов протеинкиназ - Google Patents
Аминогетероарильные соединения в качестве ингибиторов протеинкиназ Download PDFInfo
- Publication number
- EA010727B1 EA010727B1 EA200501236A EA200501236A EA010727B1 EA 010727 B1 EA010727 B1 EA 010727B1 EA 200501236 A EA200501236 A EA 200501236A EA 200501236 A EA200501236 A EA 200501236A EA 010727 B1 EA010727 B1 EA 010727B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino
- pyridin
- ethoxy
- phenyl
- chloro
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 125000005214 aminoheteroaryl group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 239
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical class NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 2,6-dichloro-3 fluorophenyl Chemical group 0.000 claims description 802
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 362
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 290
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 249
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 236
- 125000001072 heteroaryl group Chemical group 0.000 claims description 180
- 125000003118 aryl group Chemical group 0.000 claims description 157
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 153
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 126
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 112
- 125000000217 alkyl group Chemical group 0.000 claims description 99
- 229910052736 halogen Inorganic materials 0.000 claims description 78
- 150000002367 halogens Chemical class 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 64
- 125000003342 alkenyl group Chemical group 0.000 claims description 58
- 125000000304 alkynyl group Chemical group 0.000 claims description 58
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 56
- 239000002253 acid Substances 0.000 claims description 52
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 150000001408 amides Chemical class 0.000 claims description 44
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 239000012453 solvate Substances 0.000 claims description 30
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 24
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 23
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 20
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 239000010802 sludge Substances 0.000 claims description 18
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 150000004677 hydrates Chemical class 0.000 claims description 17
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 16
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 13
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052700 potassium Inorganic materials 0.000 claims description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 12
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 150000007513 acids Chemical class 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 8
- YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 claims description 8
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 8
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 8
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 8
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 claims description 8
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 8
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 8
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 8
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 8
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims description 8
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 8
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 8
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 8
- 229930192474 thiophene Natural products 0.000 claims description 8
- UFTHRGJTARTOQG-UHFFFAOYSA-N 5-(4-aminophenyl)-3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(N)C=C1 UFTHRGJTARTOQG-UHFFFAOYSA-N 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- YSVRSETXLUMJPC-UHFFFAOYSA-N 5-(4-aminophenyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(N)C=C1 YSVRSETXLUMJPC-UHFFFAOYSA-N 0.000 claims description 6
- YAAAHPOEWDXLHC-UHFFFAOYSA-N 5-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]-1h-indole-2-carboxylic acid Chemical compound NC1=NC=C(C=2C=C3C=C(NC3=CC=2)C(O)=O)C=C1OCC1=C(Cl)C=CC=C1Cl YAAAHPOEWDXLHC-UHFFFAOYSA-N 0.000 claims description 6
- HQYVQYLIERNMTM-UHFFFAOYSA-N ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CC(C)(C)N)=CN=C1N Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CC(C)(C)N)=CN=C1N HQYVQYLIERNMTM-UHFFFAOYSA-N 0.000 claims description 6
- 150000004885 piperazines Chemical class 0.000 claims description 6
- 150000003852 triazoles Chemical class 0.000 claims description 6
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 5
- MUMDVZVQLUFQIV-UHFFFAOYSA-N 5-(3-aminoprop-1-ynyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CCN)=CN=C1N MUMDVZVQLUFQIV-UHFFFAOYSA-N 0.000 claims description 5
- XQGNDISABQARPN-UHFFFAOYSA-N FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(N)C=C1 Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(N)C=C1 XQGNDISABQARPN-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 5
- QLTUUGFFRPMGKH-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(NC(=O)NCCO)C=C1 QLTUUGFFRPMGKH-UHFFFAOYSA-N 0.000 claims description 4
- XZTBNGSZLDJNLI-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,4-dichlorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(Cl)C(Cl)=C1 XZTBNGSZLDJNLI-UHFFFAOYSA-N 0.000 claims description 4
- SDXGGNKSWPLCEN-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-ethenylpyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C=C)=CN=C1N SDXGGNKSWPLCEN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- MFDDBUXFUWDGAU-UHFFFAOYSA-N 5-(aminomethyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(CN)=CN=C1N MFDDBUXFUWDGAU-UHFFFAOYSA-N 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- GDAWTQDKSMPLMQ-UHFFFAOYSA-N [4-[6-amino-5-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 GDAWTQDKSMPLMQ-UHFFFAOYSA-N 0.000 claims description 4
- FFUORYKWLCQODB-UHFFFAOYSA-N n-(3-morpholin-4-ylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCCN1CCOCC1 FFUORYKWLCQODB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- OIXSOQOJISAETD-UHFFFAOYSA-N 2-(diethylamino)ethanesulfonic acid Chemical compound CCN(CC)CCS(O)(=O)=O OIXSOQOJISAETD-UHFFFAOYSA-N 0.000 claims description 3
- QAQFKVYIYWEOIJ-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound COC1=CC=CC(COC=2C(=NC=C(C=2)C=2C=CC=CC=2)N)=C1 QAQFKVYIYWEOIJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- GGBBFUHTLXMIEO-UHFFFAOYSA-N 5-[4-(2-morpholin-4-ylethoxy)phenyl]-3-[(3-nitrophenyl)methoxy]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(OCCN3CCOCC3)=CC=2)C=C1OCC1=CC=CC([N+]([O-])=O)=C1 GGBBFUHTLXMIEO-UHFFFAOYSA-N 0.000 claims description 3
- XFXKQRFLZQWZIL-UHFFFAOYSA-N 5-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]thiophene-2-carboxylic acid Chemical compound NC1=NC=C(C=2SC(=CC=2)C(O)=O)C=C1OCC1=C(F)C=CC(F)=C1Cl XFXKQRFLZQWZIL-UHFFFAOYSA-N 0.000 claims description 3
- WSMASMMUYIRFBS-UHFFFAOYSA-N 5-phenyl-3-phenylmethoxypyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=CC=C1 WSMASMMUYIRFBS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- ODYVNXUCWDIVSA-UHFFFAOYSA-N N-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]ethanesulfonamide Chemical compound NC=1N=CC(=NC=1OC(C)C1=C(C(=CC=C1F)F)Cl)C1=CC=C(C=C1)NS(=O)(=O)CC ODYVNXUCWDIVSA-UHFFFAOYSA-N 0.000 claims description 3
- YSDLHTWNCGDLGW-UHFFFAOYSA-N [3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1N1CCCC1 YSDLHTWNCGDLGW-UHFFFAOYSA-N 0.000 claims description 3
- GCHURKJETQITJF-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 GCHURKJETQITJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 3
- WTDFFADXONGQOM-UHFFFAOYSA-N formaldehyde;hydrochloride Chemical compound Cl.O=C WTDFFADXONGQOM-UHFFFAOYSA-N 0.000 claims description 3
- VFQYQYRTIQWWPE-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCN1CCOCC1 VFQYQYRTIQWWPE-UHFFFAOYSA-N 0.000 claims description 3
- AOQMMUWCTVLKPT-UHFFFAOYSA-N n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCCN1CCCC1 AOQMMUWCTVLKPT-UHFFFAOYSA-N 0.000 claims description 3
- GBALKEWUZFZVFX-UHFFFAOYSA-N n-[4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(C)C)=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=N1 GBALKEWUZFZVFX-UHFFFAOYSA-N 0.000 claims description 3
- USXYBTKLOOTSLM-UHFFFAOYSA-N 1,5-dimethylcyclohexa-2,4-diene-1-sulfonamide Chemical compound C1(CC(=CC=C1)C)(C)S(=O)(=O)N USXYBTKLOOTSLM-UHFFFAOYSA-N 0.000 claims description 2
- UNVPBZBLHBHHOY-UHFFFAOYSA-N 1-[2-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]ethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1C(C)=O UNVPBZBLHBHHOY-UHFFFAOYSA-N 0.000 claims description 2
- GVNORZZHNRNGDW-UHFFFAOYSA-N 1-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]ethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C(C)=O)=C1 GVNORZZHNRNGDW-UHFFFAOYSA-N 0.000 claims description 2
- FAVGJHQJXTYWOL-UHFFFAOYSA-N 1-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-3-(2-morpholin-4-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)NCCN1CCOCC1 FAVGJHQJXTYWOL-UHFFFAOYSA-N 0.000 claims description 2
- NMOYRCMWPIDAPT-UHFFFAOYSA-N 1-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)NCCN1CCCC1 NMOYRCMWPIDAPT-UHFFFAOYSA-N 0.000 claims description 2
- QXRWYXPNIHEXBE-UHFFFAOYSA-N 1-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-3-(3-morpholin-4-ylpropyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)NCCCN1CCOCC1 QXRWYXPNIHEXBE-UHFFFAOYSA-N 0.000 claims description 2
- DYAUUAHGQMEAOO-UHFFFAOYSA-N 1-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-3-(3-pyrrolidin-1-ylpropyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)NCCCN1CCCC1 DYAUUAHGQMEAOO-UHFFFAOYSA-N 0.000 claims description 2
- VBGFLHMKSPCGKY-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[(2-chloro-4-fluorophenyl)methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC(F)=CC=3)Cl)C(N)=NC=2)C=C1 VBGFLHMKSPCGKY-UHFFFAOYSA-N 0.000 claims description 2
- HLCMMSZOFBAZLU-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[(4-tert-butylphenyl)methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C=CC(=CC=3)C(C)(C)C)C(N)=NC=2)C=C1 HLCMMSZOFBAZLU-UHFFFAOYSA-N 0.000 claims description 2
- PQVQPPYKNBCSIZ-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[[2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 PQVQPPYKNBCSIZ-UHFFFAOYSA-N 0.000 claims description 2
- JLSMFTMDCXWZCY-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(1-methylpiperidin-4-yl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)NC1CCN(C)CC1 JLSMFTMDCXWZCY-UHFFFAOYSA-N 0.000 claims description 2
- BCKZXQMXVQWKSS-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(1-methylpiperidin-4-yl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)NC1CCN(C)CC1 BCKZXQMXVQWKSS-UHFFFAOYSA-N 0.000 claims description 2
- UTOYBFOWKJPWPJ-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(NC(=O)NCCO)C=C1 UTOYBFOWKJPWPJ-UHFFFAOYSA-N 0.000 claims description 2
- NJJJYWKCTWXFJU-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(2-morpholin-4-ylethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)NCCN1CCOCC1 NJJJYWKCTWXFJU-UHFFFAOYSA-N 0.000 claims description 2
- VNGITLRWQBRDEX-UHFFFAOYSA-N 1-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)NCCN1CCCC1 VNGITLRWQBRDEX-UHFFFAOYSA-N 0.000 claims description 2
- NUCBKJVYWUMUJD-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-2-methylbut-3-yn-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CC(C)(C)NC(=O)NCCN1CCOCC1 NUCBKJVYWUMUJD-UHFFFAOYSA-N 0.000 claims description 2
- WGJSWGNMLVGIJT-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenoxy]-3-morpholin-4-ylpropan-2-ol Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCC(O)CN1CCOCC1 WGJSWGNMLVGIJT-UHFFFAOYSA-N 0.000 claims description 2
- BFWDNLALTZIBIW-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(1-methylpiperidin-4-yl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NC1CCN(C)CC1 BFWDNLALTZIBIW-UHFFFAOYSA-N 0.000 claims description 2
- IPEZTVCTBODPEK-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NC(=O)NCCO)C=C1 IPEZTVCTBODPEK-UHFFFAOYSA-N 0.000 claims description 2
- YEJNKQPKGUJMMK-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-morpholin-4-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NCCN1CCOCC1 YEJNKQPKGUJMMK-UHFFFAOYSA-N 0.000 claims description 2
- ZEXMMVGQCVSRRC-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NCCN1CCCC1 ZEXMMVGQCVSRRC-UHFFFAOYSA-N 0.000 claims description 2
- XWFPBJZMVURHRN-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(1-methylpiperidin-4-yl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NC1CCN(C)CC1 XWFPBJZMVURHRN-UHFFFAOYSA-N 0.000 claims description 2
- DWPMATUCAYMTAB-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-hydroxyethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NC(=O)NCCO)C=C1 DWPMATUCAYMTAB-UHFFFAOYSA-N 0.000 claims description 2
- XRWLWJIPXPLPMD-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-morpholin-4-ylethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NCCN1CCOCC1 XRWLWJIPXPLPMD-UHFFFAOYSA-N 0.000 claims description 2
- AYEAIVKAJGVMMD-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)NCCN1CCCC1 AYEAIVKAJGVMMD-UHFFFAOYSA-N 0.000 claims description 2
- WREGOQQTMQTCDW-UHFFFAOYSA-N 1-[4-[[5-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]-1h-indol-3-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CNC2=CC=C(C=3N=C(OCC=4C(=C(F)C=CC=4F)Cl)C(N)=NC=3)C=C12 WREGOQQTMQTCDW-UHFFFAOYSA-N 0.000 claims description 2
- IVJULNTWOMZJSH-UHFFFAOYSA-N 2-(cyclopropylamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CC1 IVJULNTWOMZJSH-UHFFFAOYSA-N 0.000 claims description 2
- WCHRXVJRQNYUAF-UHFFFAOYSA-N 2-[(2-amino-5-phenylpyridin-3-yl)oxymethyl]benzonitrile Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=CC=C1C#N WCHRXVJRQNYUAF-UHFFFAOYSA-N 0.000 claims description 2
- RMHMZOCBNLXUNF-UHFFFAOYSA-N 2-[4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenoxy]acetic acid Chemical compound NC1=NC=C(C=2C=CC(OCC(O)=O)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl RMHMZOCBNLXUNF-UHFFFAOYSA-N 0.000 claims description 2
- GNHUTTIJLPPYJH-UHFFFAOYSA-N 2-[4-[6-amino-5-[(2,6-difluorophenyl)methoxy]pyridin-3-yl]phenoxy]acetic acid Chemical compound NC1=NC=C(C=2C=CC(OCC(O)=O)=CC=2)C=C1OCC1=C(F)C=CC=C1F GNHUTTIJLPPYJH-UHFFFAOYSA-N 0.000 claims description 2
- RKNHGQUVWISTRU-UHFFFAOYSA-N 2-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenoxy]acetic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(OCC(O)=O)C=C1 RKNHGQUVWISTRU-UHFFFAOYSA-N 0.000 claims description 2
- LWRSWXKUPNUOOE-UHFFFAOYSA-N 2-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C(=CC=CC=2)O)C=C1OCC1=C(Cl)C=CC=C1Cl LWRSWXKUPNUOOE-UHFFFAOYSA-N 0.000 claims description 2
- BDUGAQWAVXSYPZ-UHFFFAOYSA-N 2-[[2-amino-5-(4-hydroxyphenyl)pyridin-3-yl]oxymethyl]benzonitrile Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=CC=C1C#N BDUGAQWAVXSYPZ-UHFFFAOYSA-N 0.000 claims description 2
- LPEXNZVLYCDMKJ-UHFFFAOYSA-N 2-[[2-amino-5-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridin-3-yl]oxymethyl]benzonitrile Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)C#N)C(N)=NC=2)C=C1 LPEXNZVLYCDMKJ-UHFFFAOYSA-N 0.000 claims description 2
- LPCOWVNBJCMAOG-UHFFFAOYSA-N 2-[[2-amino-5-[4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)phenyl]pyridin-3-yl]oxymethyl]benzonitrile Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=CC=C1C#N LPCOWVNBJCMAOG-UHFFFAOYSA-N 0.000 claims description 2
- UQEJESCTDTXMOF-UHFFFAOYSA-N 2-[[2-amino-5-[4-(methanesulfonamido)phenyl]pyridin-3-yl]oxymethyl]benzoic acid Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2)C(O)=O)=C1 UQEJESCTDTXMOF-UHFFFAOYSA-N 0.000 claims description 2
- LYRXQKIVTXKTEU-UHFFFAOYSA-N 2-[[5-[4-(4-acetylpiperazine-1-carbonyl)phenyl]-2-aminopyridin-3-yl]oxymethyl]benzonitrile Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)C#N)C(N)=NC=2)C=C1 LYRXQKIVTXKTEU-UHFFFAOYSA-N 0.000 claims description 2
- XARBMSAAZHEXEK-UHFFFAOYSA-N 2-piperidin-1-ylethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCCCC1 XARBMSAAZHEXEK-UHFFFAOYSA-N 0.000 claims description 2
- ZOAZVWDXJOINQJ-UHFFFAOYSA-N 3-[(2,4-dichloro-5-fluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC(F)=C(Cl)C=C1Cl ZOAZVWDXJOINQJ-UHFFFAOYSA-N 0.000 claims description 2
- CDDICWOXLQRPKR-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC(Cl)=CC=C1Cl CDDICWOXLQRPKR-UHFFFAOYSA-N 0.000 claims description 2
- ZGXGWQWGLVBNFC-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(1h-indol-2-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2NC3=CC=CC=C3C=2)C=C1OCC1=C(Cl)C=CC=C1Cl ZGXGWQWGLVBNFC-UHFFFAOYSA-N 0.000 claims description 2
- VSPFFUQAUKSOAG-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(1h-indol-4-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=3C=CNC=3C=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl VSPFFUQAUKSOAG-UHFFFAOYSA-N 0.000 claims description 2
- SGOZCJNQGFJGQH-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(1h-pyrrol-2-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2NC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl SGOZCJNQGFJGQH-UHFFFAOYSA-N 0.000 claims description 2
- ZDEXZSGPGRVRST-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(2-fluorophenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C(=CC=CC=2)F)C=C1OCC1=C(Cl)C=CC=C1Cl ZDEXZSGPGRVRST-UHFFFAOYSA-N 0.000 claims description 2
- FMYCLVAZIVTTNP-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(2-methoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2Cl)Cl)=C1 FMYCLVAZIVTTNP-UHFFFAOYSA-N 0.000 claims description 2
- FHZDNKDTBURMBE-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(2-phenoxyphenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C(=CC=CC=2)OC=2C=CC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl FHZDNKDTBURMBE-UHFFFAOYSA-N 0.000 claims description 2
- WNCKLKNMFPZRLF-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(2-phenylmethoxyphenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C(=CC=CC=2)OCC=2C=CC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl WNCKLKNMFPZRLF-UHFFFAOYSA-N 0.000 claims description 2
- KPIKMBNPPYGLDS-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(3,4-difluorophenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(F)C(F)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl KPIKMBNPPYGLDS-UHFFFAOYSA-N 0.000 claims description 2
- ZXMBERYHFCBLJE-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(3-fluoro-4-phenylmethoxyphenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(F)C(OCC=3C=CC=CC=3)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl ZXMBERYHFCBLJE-UHFFFAOYSA-N 0.000 claims description 2
- IJXOTCGHSKKWRQ-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(3-fluorophenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(F)C=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl IJXOTCGHSKKWRQ-UHFFFAOYSA-N 0.000 claims description 2
- ZYNPTNFUVBQQFS-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(3-methoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=CC(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)=C1 ZYNPTNFUVBQQFS-UHFFFAOYSA-N 0.000 claims description 2
- ZORUDJUIVIFXFN-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(3-propan-2-ylphenyl)pyridin-2-amine Chemical compound CC(C)C1=CC=CC(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)=C1 ZORUDJUIVIFXFN-UHFFFAOYSA-N 0.000 claims description 2
- AMOXCRKUHPHMAG-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(4-fluorophenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(F)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl AMOXCRKUHPHMAG-UHFFFAOYSA-N 0.000 claims description 2
- FPPODYFUQVGTKV-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(4-methoxyphenyl)pyridin-2-amine Chemical compound C1=CC(OC)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2Cl)Cl)=C1 FPPODYFUQVGTKV-UHFFFAOYSA-N 0.000 claims description 2
- RUZRWYSCYNHZAY-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(4-methylthiophen-2-yl)pyridin-2-amine Chemical compound CC1=CSC(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)=C1 RUZRWYSCYNHZAY-UHFFFAOYSA-N 0.000 claims description 2
- AGFOYFSAGDJAJW-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[2-(trifluoromethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C(=CC=CC=2)OC(F)(F)F)C=C1OCC1=C(Cl)C=CC=C1Cl AGFOYFSAGDJAJW-UHFFFAOYSA-N 0.000 claims description 2
- NZJFYKXRMJBRCA-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[2-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C(=CC=CC=2)C(F)(F)F)C=C1OCC1=C(Cl)C=CC=C1Cl NZJFYKXRMJBRCA-UHFFFAOYSA-N 0.000 claims description 2
- MFLQDFSYWLGYSY-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(2-morpholin-4-ylethoxy)phenyl]pyrazin-2-amine Chemical compound NC1=NC=C(C=2C=C(OCCN3CCOCC3)C=CC=2)N=C1OCC1=C(Cl)C=CC=C1Cl MFLQDFSYWLGYSY-UHFFFAOYSA-N 0.000 claims description 2
- ACMWYINFAGOJTR-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(OCCN3CCOCC3)C=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl ACMWYINFAGOJTR-UHFFFAOYSA-N 0.000 claims description 2
- WCSMCFPDAJEIAG-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(morpholin-4-ylmethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCOCC4)=CNC3=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl WCSMCFPDAJEIAG-UHFFFAOYSA-N 0.000 claims description 2
- HSQRKDRNVAPSEC-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(piperidin-1-ylmethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCCCC4)=CNC3=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl HSQRKDRNVAPSEC-UHFFFAOYSA-N 0.000 claims description 2
- VJGPKLLDBGFYLK-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(pyrrolidin-1-ylmethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCCC4)=CNC3=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl VJGPKLLDBGFYLK-UHFFFAOYSA-N 0.000 claims description 2
- RHOHOTQFEFVZKI-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(trifluoromethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(OC(F)(F)F)C=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl RHOHOTQFEFVZKI-UHFFFAOYSA-N 0.000 claims description 2
- XSVRBQRFVXYPLV-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-[(2,6-dimethylmorpholin-4-yl)methyl]-1h-indol-5-yl]pyridin-2-amine Chemical compound C1C(C)OC(C)CN1CC1=CNC2=CC=C(C=3C=C(OCC=4C(=CC=CC=4Cl)Cl)C(N)=NC=3)C=C12 XSVRBQRFVXYPLV-UHFFFAOYSA-N 0.000 claims description 2
- SMSQIPHRBOXGKG-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrazin-2-amine Chemical compound NC1=NC=C(C=2C=CC(OCCN3CCOCC3)=CC=2)N=C1OCC1=C(Cl)C=CC=C1Cl SMSQIPHRBOXGKG-UHFFFAOYSA-N 0.000 claims description 2
- SWSODYAMDICARQ-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(OCCN3CCOCC3)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl SWSODYAMDICARQ-UHFFFAOYSA-N 0.000 claims description 2
- CEPMKUPNGDQLBX-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[4-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1OCC1=C(Cl)C=CC=C1Cl CEPMKUPNGDQLBX-UHFFFAOYSA-N 0.000 claims description 2
- SURCUYLOXYEWLT-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl SURCUYLOXYEWLT-UHFFFAOYSA-N 0.000 claims description 2
- PFEIELQLCNTFEY-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-pyridin-2-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2N=CC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl PFEIELQLCNTFEY-UHFFFAOYSA-N 0.000 claims description 2
- AACQAJOXZPVTSQ-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-pyridin-3-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl AACQAJOXZPVTSQ-UHFFFAOYSA-N 0.000 claims description 2
- ZVHFPCWDJOSKIL-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-pyrimidin-5-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=NC=2)C=C1OCC1=C(Cl)C=CC=C1Cl ZVHFPCWDJOSKIL-UHFFFAOYSA-N 0.000 claims description 2
- BJRKVFDMTVUDPT-UHFFFAOYSA-N 3-[(2,6-difluoro-3-methylphenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound CC1=CC=C(F)C(COC=2C(=NC=C(C=2)C=2C=CC=CC=2)N)=C1F BJRKVFDMTVUDPT-UHFFFAOYSA-N 0.000 claims description 2
- IXKDTCREAJHFDJ-UHFFFAOYSA-N 3-[(2,6-difluorophenyl)methoxy]-5-(1h-indol-4-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=3C=CNC=3C=CC=2)C=C1OCC1=C(F)C=CC=C1F IXKDTCREAJHFDJ-UHFFFAOYSA-N 0.000 claims description 2
- YWGWVUMLUYNBJV-UHFFFAOYSA-N 3-[(2,6-difluorophenyl)methoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(OCCN3CCOCC3)=CC=2)C=C1OCC1=C(F)C=CC=C1F YWGWVUMLUYNBJV-UHFFFAOYSA-N 0.000 claims description 2
- KEXZUPQPVIQEJP-UHFFFAOYSA-N 3-[(2,6-difluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(F)C=CC=C1F KEXZUPQPVIQEJP-UHFFFAOYSA-N 0.000 claims description 2
- CYWZUDGGPWEFDR-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-(1h-indol-5-yl)pyrazin-2-amine Chemical compound NC1=NC=C(C=2C=C3C=CNC3=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl CYWZUDGGPWEFDR-UHFFFAOYSA-N 0.000 claims description 2
- BSSHQYHXECSEOH-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[2-[(dimethylamino)methyl]phenyl]pyridin-2-amine Chemical compound CN(C)CC1=CC=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=C1 BSSHQYHXECSEOH-UHFFFAOYSA-N 0.000 claims description 2
- LLSSUEOZTDWYKI-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[3-(morpholin-4-ylmethyl)-1h-indol-5-yl]pyrazin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCOCC4)=CNC3=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl LLSSUEOZTDWYKI-UHFFFAOYSA-N 0.000 claims description 2
- VYZOESQVOFQNBG-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[3-(morpholin-4-ylmethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCOCC4)=CNC3=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl VYZOESQVOFQNBG-UHFFFAOYSA-N 0.000 claims description 2
- CWSITALBFZSIND-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[3-(pyrrolidin-1-ylmethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C(CN4CCCC4)=CNC3=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl CWSITALBFZSIND-UHFFFAOYSA-N 0.000 claims description 2
- PFRUCUSYCGTLRJ-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC(OCCN3CCOCC3)=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl PFRUCUSYCGTLRJ-UHFFFAOYSA-N 0.000 claims description 2
- ILPDUKPYGZXZBA-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl ILPDUKPYGZXZBA-UHFFFAOYSA-N 0.000 claims description 2
- PAOKSPXHECNCQD-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-pyridin-2-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2N=CC=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl PAOKSPXHECNCQD-UHFFFAOYSA-N 0.000 claims description 2
- DOLBRUGYHJVKJM-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-pyridin-3-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl DOLBRUGYHJVKJM-UHFFFAOYSA-N 0.000 claims description 2
- AVXUEZLHWBTGRE-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-pyridin-4-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CN=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl AVXUEZLHWBTGRE-UHFFFAOYSA-N 0.000 claims description 2
- VQQDCDDYVNCSJG-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-pyrimidin-5-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=NC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl VQQDCDDYVNCSJG-UHFFFAOYSA-N 0.000 claims description 2
- SMGUMDIUPLNKAW-UHFFFAOYSA-N 3-[(2-chloro-4-fluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=C(F)C=C1Cl SMGUMDIUPLNKAW-UHFFFAOYSA-N 0.000 claims description 2
- GDECLRLFRGUYHM-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylphenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound CC1=CC=C(F)C(COC=2C(=NC=C(C=2)C=2C=CC=CC=2)N)=C1Cl GDECLRLFRGUYHM-UHFFFAOYSA-N 0.000 claims description 2
- YDKNBTOQUDLROF-UHFFFAOYSA-N 3-[(2-chloro-6-fluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(F)C=CC=C1Cl YDKNBTOQUDLROF-UHFFFAOYSA-N 0.000 claims description 2
- DRPHRSQNAYCXCV-UHFFFAOYSA-N 3-[(2-chlorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=CC=C1Cl DRPHRSQNAYCXCV-UHFFFAOYSA-N 0.000 claims description 2
- WEWSGPMWAKPODL-UHFFFAOYSA-N 3-[(2-chlorophenyl)methoxy]-5-pyrimidin-5-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=NC=2)C=C1OCC1=CC=CC=C1Cl WEWSGPMWAKPODL-UHFFFAOYSA-N 0.000 claims description 2
- HZIRWVKZRQYCIO-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=C(Cl)C(Cl)=C1 HZIRWVKZRQYCIO-UHFFFAOYSA-N 0.000 claims description 2
- NVTJHGAQPFSJME-UHFFFAOYSA-N 3-[(3-chloro-2,6-difluorophenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(F)C=CC(Cl)=C1F NVTJHGAQPFSJME-UHFFFAOYSA-N 0.000 claims description 2
- RCBVGABYRSVBSR-UHFFFAOYSA-N 3-[(3-fluoro-4-methoxyphenyl)methoxy]-5-phenylpyridin-2-amine Chemical compound C1=C(F)C(OC)=CC=C1COC1=CC(C=2C=CC=CC=2)=CN=C1N RCBVGABYRSVBSR-UHFFFAOYSA-N 0.000 claims description 2
- IOLKFKGEXBZRKU-UHFFFAOYSA-N 3-[(3-fluoro-6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-yl)oxy]-5-(1h-pyrazol-4-yl)pyridin-2-amine Chemical compound C1=C(OC2C3=CC(F)=CC=C3CCCC2)C(N)=NC=C1C=1C=NNC=1 IOLKFKGEXBZRKU-UHFFFAOYSA-N 0.000 claims description 2
- GYOPVQBSBPSLBV-UHFFFAOYSA-N 3-[(3-fluoro-6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-yl)oxy]-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound C1=C(OC2C3=CC(F)=CC=C3CCCC2)C(N)=NC=C1C(C=C1)=CC=C1OCCN1CCCC1 GYOPVQBSBPSLBV-UHFFFAOYSA-N 0.000 claims description 2
- WRZLHOARWTYWES-UHFFFAOYSA-N 3-[(4-chlorophenyl)methoxy]-5-pyridin-2-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2N=CC=CC=2)C=C1OCC1=CC=C(Cl)C=C1 WRZLHOARWTYWES-UHFFFAOYSA-N 0.000 claims description 2
- YUMYJTMJKHVIDD-UHFFFAOYSA-N 3-[(4-chlorophenyl)methoxy]-5-pyrimidin-5-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=NC=2)C=C1OCC1=CC=C(Cl)C=C1 YUMYJTMJKHVIDD-UHFFFAOYSA-N 0.000 claims description 2
- QUHCDNXFFCWISW-UHFFFAOYSA-N 3-[(5-chloro-1-benzothiophen-3-yl)methoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound C1=C(OCC=2C3=CC(Cl)=CC=C3SC=2)C(N)=NC=C1C(C=C1)=CC=C1OCCN1CCOCC1 QUHCDNXFFCWISW-UHFFFAOYSA-N 0.000 claims description 2
- HFWGLLLEYWODRG-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-methylpyrazol-4-yl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C=1C=NN(C)C=1 HFWGLLLEYWODRG-UHFFFAOYSA-N 0.000 claims description 2
- VTOQQRYPFKINSB-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1h-pyrazol-4-yl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C=1C=NNC=1 VTOQQRYPFKINSB-UHFFFAOYSA-N 0.000 claims description 2
- MPMFYUWXDLYCHJ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1h-pyrrol-2-yl)pyrazin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=CN1 MPMFYUWXDLYCHJ-UHFFFAOYSA-N 0.000 claims description 2
- COWLCGJSUMZAAM-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,4-dimethoxyphenyl)pyridin-2-amine Chemical compound COC1=CC(OC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 COWLCGJSUMZAAM-UHFFFAOYSA-N 0.000 claims description 2
- YADJHUHSWBRHLU-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,5-dichlorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(Cl)=CC=C1Cl YADJHUHSWBRHLU-UHFFFAOYSA-N 0.000 claims description 2
- WDESDWWUOWAWBJ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,5-dimethoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=C(OC)C(C=2C=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)=C1 WDESDWWUOWAWBJ-UHFFFAOYSA-N 0.000 claims description 2
- KJDYMJUCLYOMHY-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,6-dimethoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=CC(OC)=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 KJDYMJUCLYOMHY-UHFFFAOYSA-N 0.000 claims description 2
- ORZOAORYDYFSGQ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,6-dimethylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=C(C)C=CC=C1C ORZOAORYDYFSGQ-UHFFFAOYSA-N 0.000 claims description 2
- ILHZBPMHFPEVBW-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2-ethoxyphenyl)pyridin-2-amine Chemical compound CCOC1=CC=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 ILHZBPMHFPEVBW-UHFFFAOYSA-N 0.000 claims description 2
- HTCJWAXIFCITFN-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2-fluorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1F HTCJWAXIFCITFN-UHFFFAOYSA-N 0.000 claims description 2
- ZEVBSGXPBCWCDP-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2-methoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 ZEVBSGXPBCWCDP-UHFFFAOYSA-N 0.000 claims description 2
- QNSSKBJSBQSEAM-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2-methylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1C QNSSKBJSBQSEAM-UHFFFAOYSA-N 0.000 claims description 2
- ZJRKDOPJBUEEHP-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,4-difluorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(F)C(F)=C1 ZJRKDOPJBUEEHP-UHFFFAOYSA-N 0.000 claims description 2
- UAJDKYCVAWVJSH-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,4-dimethoxyphenyl)pyridin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 UAJDKYCVAWVJSH-UHFFFAOYSA-N 0.000 claims description 2
- POAPBDCVVVNDEO-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,5-dichlorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(Cl)=CC(Cl)=C1 POAPBDCVVVNDEO-UHFFFAOYSA-N 0.000 claims description 2
- WANBJHKKYHNYAL-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,5-difluorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(F)=CC(F)=C1 WANBJHKKYHNYAL-UHFFFAOYSA-N 0.000 claims description 2
- RJBYEHGZSRBVLU-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3,5-dimethylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(C)=CC(C)=C1 RJBYEHGZSRBVLU-UHFFFAOYSA-N 0.000 claims description 2
- JRMQMTDKCYLDRE-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-ethoxyphenyl)pyridin-2-amine Chemical compound CCOC1=CC=CC(C=2C=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)=C1 JRMQMTDKCYLDRE-UHFFFAOYSA-N 0.000 claims description 2
- SFVIAMCOTNJXPU-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-fluorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(F)=C1 SFVIAMCOTNJXPU-UHFFFAOYSA-N 0.000 claims description 2
- NPYPJWLBKZYPOB-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-methoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=CC(C=2C=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)=C1 NPYPJWLBKZYPOB-UHFFFAOYSA-N 0.000 claims description 2
- FTTLXHSVIIMSHE-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-methylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C)=C1 FTTLXHSVIIMSHE-UHFFFAOYSA-N 0.000 claims description 2
- FUIPASITSJNXNZ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-phenylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C1=CC=CC=C1 FUIPASITSJNXNZ-UHFFFAOYSA-N 0.000 claims description 2
- DYNRMPDJUVQGCQ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(3-propan-2-ylphenyl)pyridin-2-amine Chemical compound CC(C)C1=CC=CC(C=2C=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)=C1 DYNRMPDJUVQGCQ-UHFFFAOYSA-N 0.000 claims description 2
- NUYJSTZRPNDGKI-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(4-fluoro-3-methylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(F)C(C)=C1 NUYJSTZRPNDGKI-UHFFFAOYSA-N 0.000 claims description 2
- RTKAKFQOKXSFKB-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(5-fluoro-2-methoxyphenyl)pyridin-2-amine Chemical compound COC1=CC=C(F)C=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 RTKAKFQOKXSFKB-UHFFFAOYSA-N 0.000 claims description 2
- UFRZNORAJVCIHO-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(6-methoxy-1-methylbenzimidazol-2-yl)pyridin-2-amine Chemical compound CN1C2=CC(OC)=CC=C2N=C1C(C=1)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl UFRZNORAJVCIHO-UHFFFAOYSA-N 0.000 claims description 2
- LKXOKQQZHBNQND-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(6-methoxy-1h-benzimidazol-2-yl)pyridin-2-amine Chemical compound N1C2=CC(OC)=CC=C2N=C1C(C=1)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl LKXOKQQZHBNQND-UHFFFAOYSA-N 0.000 claims description 2
- OVBMSXLZKBDWMA-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(=C1)C=NN1CCN1CCOCC1 OVBMSXLZKBDWMA-UHFFFAOYSA-N 0.000 claims description 2
- NDJSFYKERREBAK-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-[2-[di(propan-2-yl)amino]ethyl]pyrazol-4-yl]pyridin-2-amine Chemical compound C1=NN(CCN(C(C)C)C(C)C)C=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 NDJSFYKERREBAK-UHFFFAOYSA-N 0.000 claims description 2
- XDCSOCBYXINZSS-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[2-(trifluoromethoxy)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1OC(F)(F)F XDCSOCBYXINZSS-UHFFFAOYSA-N 0.000 claims description 2
- KBBLNKNCESYWQZ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[2-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1C(F)(F)F KBBLNKNCESYWQZ-UHFFFAOYSA-N 0.000 claims description 2
- QWJQHHSLHJRARA-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[3-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1OCCN1CCOCC1 QWJQHHSLHJRARA-UHFFFAOYSA-N 0.000 claims description 2
- RBYAMWQNIURIAG-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[3-(trifluoromethoxy)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(OC(F)(F)F)=C1 RBYAMWQNIURIAG-UHFFFAOYSA-N 0.000 claims description 2
- VRKQOMCQJPMQKM-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[3-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C(F)(F)F)=C1 VRKQOMCQJPMQKM-UHFFFAOYSA-N 0.000 claims description 2
- BIJNXYLIHJXIQR-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(1-methylpiperidin-4-yl)oxyphenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OC1CCN(C)CC1 BIJNXYLIHJXIQR-UHFFFAOYSA-N 0.000 claims description 2
- WNFQXKVUUREHOS-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCCN1CCOCC1 WNFQXKVUUREHOS-UHFFFAOYSA-N 0.000 claims description 2
- QFEABENCSHTOSU-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(2-piperazin-1-ylpropan-2-yl)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(C)(C)N1CCNCC1 QFEABENCSHTOSU-UHFFFAOYSA-N 0.000 claims description 2
- YBAWBUMTBMFMDW-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCCN1CCCC1 YBAWBUMTBMFMDW-UHFFFAOYSA-N 0.000 claims description 2
- QRQHIMJPSYYNFX-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(morpholin-4-ylmethyl)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1CN1CCOCC1 QRQHIMJPSYYNFX-UHFFFAOYSA-N 0.000 claims description 2
- SYOARNJRTYFJCI-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-[(1-methylpiperidin-3-yl)methoxy]phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCC1CCCN(C)C1 SYOARNJRTYFJCI-UHFFFAOYSA-N 0.000 claims description 2
- HSWAKFCSWBLZIQ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1S(=O)(=O)N1CCCN(C)CC1 HSWAKFCSWBLZIQ-UHFFFAOYSA-N 0.000 claims description 2
- VEAUJFGSTGSMGP-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCCC1CCCN1C VEAUJFGSTGSMGP-UHFFFAOYSA-N 0.000 claims description 2
- WAOGFCHAMUDCAU-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-[2-(diethylamino)ethoxy]phenyl]pyridin-2-amine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 WAOGFCHAMUDCAU-UHFFFAOYSA-N 0.000 claims description 2
- CBEAOSPAGYPRAI-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-[2-[di(propan-2-yl)amino]ethoxy]phenyl]pyridin-2-amine Chemical compound C1=CC(OCCN(C(C)C)C(C)C)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 CBEAOSPAGYPRAI-UHFFFAOYSA-N 0.000 claims description 2
- XVADSHHYRFVFSJ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-phenylpyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1 XVADSHHYRFVFSJ-UHFFFAOYSA-N 0.000 claims description 2
- ASMPFCDZSRGBEK-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-pyridin-4-ylpyrazin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=NC=C1 ASMPFCDZSRGBEK-UHFFFAOYSA-N 0.000 claims description 2
- CNIWQVXAMMHUDN-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-thiophen-3-ylpyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C=1C=CSC=1 CNIWQVXAMMHUDN-UHFFFAOYSA-N 0.000 claims description 2
- BUDUFOGTNGXDRI-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)-2-methylpropoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrazin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C(C)C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1OCCN1CCOCC1 BUDUFOGTNGXDRI-UHFFFAOYSA-N 0.000 claims description 2
- HIHZCRHHTKVVEL-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(2-cyclohexylethoxy)pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCCC1CCCCC1 HIHZCRHHTKVVEL-UHFFFAOYSA-N 0.000 claims description 2
- HRAIFXPIVBCLLQ-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(2-ethylbutoxy)pyridin-2-amine Chemical compound CCC(CC)COC1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2F)Cl)=C1 HRAIFXPIVBCLLQ-UHFFFAOYSA-N 0.000 claims description 2
- VEUWWJDITPZVSB-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(2-methylpropoxy)pyridin-2-amine Chemical compound CC(C)COC1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2F)Cl)=C1 VEUWWJDITPZVSB-UHFFFAOYSA-N 0.000 claims description 2
- BMNOPKQSMSLYJS-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(2-phenylethoxy)pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCCC1=CC=CC=C1 BMNOPKQSMSLYJS-UHFFFAOYSA-N 0.000 claims description 2
- JVDSLXIQFSTHRG-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(3-methylbutoxy)pyridin-2-amine Chemical compound CC(C)CCOC1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2F)Cl)=C1 JVDSLXIQFSTHRG-UHFFFAOYSA-N 0.000 claims description 2
- VYJNNPYHFQKCCH-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(cyclohexylmethoxy)pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCC1CCCCC1 VYJNNPYHFQKCCH-UHFFFAOYSA-N 0.000 claims description 2
- WHWWXOOOTGACLI-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(pyridin-2-ylmethoxy)pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCC1=CC=CC=N1 WHWWXOOOTGACLI-UHFFFAOYSA-N 0.000 claims description 2
- FVBMMNOAEIZEJL-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-(pyridin-4-ylmethoxy)pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCC1=CC=NC=C1 FVBMMNOAEIZEJL-UHFFFAOYSA-N 0.000 claims description 2
- SCNCUFZJEVTUTN-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-[3-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1OCCN1CCOCC1 SCNCUFZJEVTUTN-UHFFFAOYSA-N 0.000 claims description 2
- UMLJJYWTNXIPEE-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrazin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1OCCN1CCOCC1 UMLJJYWTNXIPEE-UHFFFAOYSA-N 0.000 claims description 2
- XJANXPGIVBNTLT-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCCN1CCOCC1 XJANXPGIVBNTLT-UHFFFAOYSA-N 0.000 claims description 2
- WHEXULPSAHOTEU-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-phenylmethoxypyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1OCC1=CC=CC=C1 WHEXULPSAHOTEU-UHFFFAOYSA-N 0.000 claims description 2
- NWDNATZNJPQLSX-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-propoxypyridin-2-amine Chemical compound CCCOC1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2F)Cl)=C1 NWDNATZNJPQLSX-UHFFFAOYSA-N 0.000 claims description 2
- JULDPQKCXRFFMR-UHFFFAOYSA-N 3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]-5-pyrimidin-5-ylpyridin-2-amine Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CN=CN=C1 JULDPQKCXRFFMR-UHFFFAOYSA-N 0.000 claims description 2
- LFYJIACDNGAJBU-UHFFFAOYSA-N 3-[1-[2-amino-5-[4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)phenyl]pyridin-3-yl]oxyethyl]benzoic acid Chemical compound C=1C=CC(C(O)=O)=CC=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 LFYJIACDNGAJBU-UHFFFAOYSA-N 0.000 claims description 2
- RTPJEYHUQJHWOQ-UHFFFAOYSA-N 3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=C(C=CC=2)C(O)=O)N=C1OCC1=C(F)C=CC(F)=C1Cl RTPJEYHUQJHWOQ-UHFFFAOYSA-N 0.000 claims description 2
- XJMUVFHQFXYBBT-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=CC(C(O)=O)=C1 XJMUVFHQFXYBBT-UHFFFAOYSA-N 0.000 claims description 2
- WUJPROMUUZRGIQ-UHFFFAOYSA-N 3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=CC(C(O)=O)=C1 WUJPROMUUZRGIQ-UHFFFAOYSA-N 0.000 claims description 2
- NIHHMBINDSRXPK-UHFFFAOYSA-N 3-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=C(C=CC=2)C(O)=O)N=C1OCC1=CC=CC(F)=C1C(F)(F)F NIHHMBINDSRXPK-UHFFFAOYSA-N 0.000 claims description 2
- FVACDUYIWZFVEZ-UHFFFAOYSA-N 3-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=C(C=CC=2)C(O)=O)C=C1OCC1=C(Cl)C=CC=C1Cl FVACDUYIWZFVEZ-UHFFFAOYSA-N 0.000 claims description 2
- HLFRMZWKKUBATG-UHFFFAOYSA-N 3-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=C(O)C=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl HLFRMZWKKUBATG-UHFFFAOYSA-N 0.000 claims description 2
- QBEFFVSDAFKOKA-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzonitrile Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C#N)=C1 QBEFFVSDAFKOKA-UHFFFAOYSA-N 0.000 claims description 2
- BAKHDCZFCOFSNV-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenol Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(O)=C1 BAKHDCZFCOFSNV-UHFFFAOYSA-N 0.000 claims description 2
- JFHVYKSDKWXQOP-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynylurea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CCNC(N)=O)=CN=C1N JFHVYKSDKWXQOP-UHFFFAOYSA-N 0.000 claims description 2
- SKBFHGFPIREMQA-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C(O)=O)=C1 SKBFHGFPIREMQA-UHFFFAOYSA-N 0.000 claims description 2
- YQWQKKUCNUJMEI-UHFFFAOYSA-N 3-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C(O)=O)=C1 YQWQKKUCNUJMEI-UHFFFAOYSA-N 0.000 claims description 2
- BZXPPIPJZGEOBD-UHFFFAOYSA-N 3-[[2-chloro-3-(trifluoromethyl)phenyl]methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC=CC(C(F)(F)F)=C1Cl BZXPPIPJZGEOBD-UHFFFAOYSA-N 0.000 claims description 2
- YWAQPQCURJNXLW-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)phenyl]methoxy]-5-phenylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=CC(C(F)(F)F)=CC=C1Cl YWAQPQCURJNXLW-UHFFFAOYSA-N 0.000 claims description 2
- WWUPUYHDSLLEEY-UHFFFAOYSA-N 3-[[2-chloro-6-(1h-indol-4-yl)phenyl]methoxy]-5-(1h-indol-4-yl)pyridin-2-amine Chemical compound C1=C(OCC=2C(=CC=CC=2Cl)C=2C=3C=CNC=3C=CC=2)C(N)=NC=C1C1=CC=CC2=C1C=CN2 WWUPUYHDSLLEEY-UHFFFAOYSA-N 0.000 claims description 2
- YQRPMKJBPOSYSE-UHFFFAOYSA-N 3-phenylmethoxy-5-pyridin-2-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2N=CC=CC=2)C=C1OCC1=CC=CC=C1 YQRPMKJBPOSYSE-UHFFFAOYSA-N 0.000 claims description 2
- KZTPEWOMOPCWMG-UHFFFAOYSA-N 3-phenylmethoxy-5-pyridin-3-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=CC=2)C=C1OCC1=CC=CC=C1 KZTPEWOMOPCWMG-UHFFFAOYSA-N 0.000 claims description 2
- QODDFZADLSZHNS-UHFFFAOYSA-N 3-phenylmethoxy-5-pyrimidin-5-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=NC=2)C=C1OCC1=CC=CC=C1 QODDFZADLSZHNS-UHFFFAOYSA-N 0.000 claims description 2
- QBXSJRUVDVDJAV-UHFFFAOYSA-N 4-(6-amino-5-phenylmethoxypyridin-3-yl)phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=CC=C1 QBXSJRUVDVDJAV-UHFFFAOYSA-N 0.000 claims description 2
- HDHYPOMBOBVLAT-UHFFFAOYSA-N 4-[2-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenoxy]acetyl]piperazine-1-carboxylic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1OCC(=O)N1CCN(C(O)=O)CC1 HDHYPOMBOBVLAT-UHFFFAOYSA-N 0.000 claims description 2
- WRPSVTYPVLZZGI-UHFFFAOYSA-N 4-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]piperidin-4-ol Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C1(O)CCNCC1 WRPSVTYPVLZZGI-UHFFFAOYSA-N 0.000 claims description 2
- WTTPZQJDKCHNMB-UHFFFAOYSA-N 4-[5-amino-6-[(2,6-dichlorophenyl)methoxy]pyrazin-2-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)N=C1OCC1=C(Cl)C=CC=C1Cl WTTPZQJDKCHNMB-UHFFFAOYSA-N 0.000 claims description 2
- NLVCIDOTZVKKNP-UHFFFAOYSA-N 4-[5-amino-6-[(2,6-dichlorophenyl)methoxy]pyrazin-2-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)N=C1OCC1=C(Cl)C=CC=C1Cl NLVCIDOTZVKKNP-UHFFFAOYSA-N 0.000 claims description 2
- CRNTZKLFRBMOGK-UHFFFAOYSA-N 4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)N=C1OCC1=C(F)C=CC(F)=C1Cl CRNTZKLFRBMOGK-UHFFFAOYSA-N 0.000 claims description 2
- IGRNEOXYFPOWTJ-UHFFFAOYSA-N 4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(C(O)=O)C=C1 IGRNEOXYFPOWTJ-UHFFFAOYSA-N 0.000 claims description 2
- NIXJFIIRABNFIR-UHFFFAOYSA-N 4-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(C(O)=O)C=C1 NIXJFIIRABNFIR-UHFFFAOYSA-N 0.000 claims description 2
- QKGUKBYJWUJUCB-UHFFFAOYSA-N 4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(C(O)=O)C=C1 QKGUKBYJWUJUCB-UHFFFAOYSA-N 0.000 claims description 2
- SQNMZUMWPVVKIG-UHFFFAOYSA-N 4-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)N=C1OCC1=CC=CC(F)=C1C(F)(F)F SQNMZUMWPVVKIG-UHFFFAOYSA-N 0.000 claims description 2
- IPZNXBGVBBRIQL-UHFFFAOYSA-N 4-[6-amino-5-[(2,4-dichlorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=C(Cl)C=C1Cl IPZNXBGVBBRIQL-UHFFFAOYSA-N 0.000 claims description 2
- BRZQXFAQLGKAIG-UHFFFAOYSA-N 4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=C(Cl)C=CC=C1Cl BRZQXFAQLGKAIG-UHFFFAOYSA-N 0.000 claims description 2
- UKLUNDRJHLHCRQ-UHFFFAOYSA-N 4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl UKLUNDRJHLHCRQ-UHFFFAOYSA-N 0.000 claims description 2
- XFHKZERSWQSOML-UHFFFAOYSA-N 4-[6-amino-5-[(2,6-difluorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=C(F)C=CC=C1F XFHKZERSWQSOML-UHFFFAOYSA-N 0.000 claims description 2
- PWPOQJDJSWTAKB-UHFFFAOYSA-N 4-[6-amino-5-[(2,6-difluorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=C(F)C=CC=C1F PWPOQJDJSWTAKB-UHFFFAOYSA-N 0.000 claims description 2
- DZCRAQUWHHVPCL-UHFFFAOYSA-N 4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=C(F)C=CC(F)=C1Cl DZCRAQUWHHVPCL-UHFFFAOYSA-N 0.000 claims description 2
- GJCARVIZAHETSG-UHFFFAOYSA-N 4-[6-amino-5-[(2-chloro-4-fluorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=C(F)C=C1Cl GJCARVIZAHETSG-UHFFFAOYSA-N 0.000 claims description 2
- OPDWCWKJKCVRBD-UHFFFAOYSA-N 4-[6-amino-5-[(2-chloro-4-fluorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=C(F)C=C1Cl OPDWCWKJKCVRBD-UHFFFAOYSA-N 0.000 claims description 2
- MAQONCGTVMTWJE-UHFFFAOYSA-N 4-[6-amino-5-[(2-chloro-6-fluorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=C(F)C=CC=C1Cl MAQONCGTVMTWJE-UHFFFAOYSA-N 0.000 claims description 2
- GDNDUZKPRAQANT-UHFFFAOYSA-N 4-[6-amino-5-[(2-chlorophenyl)methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=CC=C1Cl GDNDUZKPRAQANT-UHFFFAOYSA-N 0.000 claims description 2
- CZUHRGQODHIZQM-UHFFFAOYSA-N 4-[6-amino-5-[(4-tert-butylphenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1COC1=CC(C=2C=CC(=CC=2)C(O)=O)=CN=C1N CZUHRGQODHIZQM-UHFFFAOYSA-N 0.000 claims description 2
- YSPRSILEQJWTIW-UHFFFAOYSA-N 4-[6-amino-5-[(4-tert-butylphenyl)methoxy]pyridin-3-yl]phenol Chemical compound C1=CC(C(C)(C)C)=CC=C1COC1=CC(C=2C=CC(O)=CC=2)=CN=C1N YSPRSILEQJWTIW-UHFFFAOYSA-N 0.000 claims description 2
- WNWABINNQARCRK-UHFFFAOYSA-N 4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(C(O)=O)C=C1 WNWABINNQARCRK-UHFFFAOYSA-N 0.000 claims description 2
- XCXKJUREQVFLJP-UHFFFAOYSA-N 4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzonitrile Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(C#N)C=C1 XCXKJUREQVFLJP-UHFFFAOYSA-N 0.000 claims description 2
- JYHLZOQHPGUWQI-UHFFFAOYSA-N 4-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(C(O)=O)C=C1 JYHLZOQHPGUWQI-UHFFFAOYSA-N 0.000 claims description 2
- ABGWHLZDLZSWQM-UHFFFAOYSA-N 4-[6-amino-5-[[2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=CC=C1C(F)(F)F ABGWHLZDLZSWQM-UHFFFAOYSA-N 0.000 claims description 2
- YEXFJAUCPKFQHE-UHFFFAOYSA-N 4-[6-amino-5-[[2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenol Chemical compound NC1=NC=C(C=2C=CC(O)=CC=2)C=C1OCC1=CC=CC=C1C(F)(F)F YEXFJAUCPKFQHE-UHFFFAOYSA-N 0.000 claims description 2
- RUVSHHYMKYQLBF-UHFFFAOYSA-N 4-[6-amino-5-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=CC(F)=C1C(F)(F)F RUVSHHYMKYQLBF-UHFFFAOYSA-N 0.000 claims description 2
- KNWWGBNAUNTSRV-UHFFFAOYSA-N 4-methylpiperazine-1-carboxylic acid Chemical compound CN1CCN(C(O)=O)CC1 KNWWGBNAUNTSRV-UHFFFAOYSA-N 0.000 claims description 2
- QBDYZOZZZSCNLM-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-3-[(2,6-dichlorophenyl)methoxy]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3OCOC3=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl QBDYZOZZZSCNLM-UHFFFAOYSA-N 0.000 claims description 2
- XFASYXXTUXUFAP-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound C=1C(C=2C=C3OCOC3=CC=2)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl XFASYXXTUXUFAP-UHFFFAOYSA-N 0.000 claims description 2
- BXZLSDHOLXJQQU-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound C=1C(C=2SC3=CC=CC=C3C=2)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl BXZLSDHOLXJQQU-UHFFFAOYSA-N 0.000 claims description 2
- BSPUDOPKLJMOCF-UHFFFAOYSA-N 5-(2-chlorophenyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1Cl BSPUDOPKLJMOCF-UHFFFAOYSA-N 0.000 claims description 2
- IJWRQPZMEXUNGV-UHFFFAOYSA-N 5-(3-aminophenyl)-3-[(2,6-dichlorophenyl)methoxy]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)=C1 IJWRQPZMEXUNGV-UHFFFAOYSA-N 0.000 claims description 2
- HWBRNVBQFVKCEI-UHFFFAOYSA-N 5-(3-chloro-4-fluorophenyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(F)C(Cl)=C1 HWBRNVBQFVKCEI-UHFFFAOYSA-N 0.000 claims description 2
- OTBNLHLOBJNMJT-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(Cl)=C1 OTBNLHLOBJNMJT-UHFFFAOYSA-N 0.000 claims description 2
- PQGSISXSLMNAMW-UHFFFAOYSA-N 5-(4-aminophenyl)-3-[(2,6-dichlorophenyl)methoxy]pyrazin-2-amine Chemical compound C1=CC(N)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2Cl)Cl)=N1 PQGSISXSLMNAMW-UHFFFAOYSA-N 0.000 claims description 2
- RANPANZLZLMWLA-UHFFFAOYSA-N 5-(4-aminophenyl)-3-[(2,6-dichlorophenyl)methoxy]pyridin-2-amine Chemical compound C1=CC(N)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2Cl)Cl)=C1 RANPANZLZLMWLA-UHFFFAOYSA-N 0.000 claims description 2
- LOAYKROQUAAURL-UHFFFAOYSA-N 5-(5-chloro-2-methoxyphenyl)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound COC1=CC=C(Cl)C=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 LOAYKROQUAAURL-UHFFFAOYSA-N 0.000 claims description 2
- VMYWWNULDCJHOE-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-3-[(2,6-dichlorophenyl)methoxy]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2Cl)Cl)=C1 VMYWWNULDCJHOE-UHFFFAOYSA-N 0.000 claims description 2
- LYHAQOVZAARKJB-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-3-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=C1 LYHAQOVZAARKJB-UHFFFAOYSA-N 0.000 claims description 2
- ZNFMGLQGOOACKI-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-3-[(2-chlorophenyl)methoxy]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2)Cl)=C1 ZNFMGLQGOOACKI-UHFFFAOYSA-N 0.000 claims description 2
- TXPABVKEIGUXHT-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-3-[(4-chlorophenyl)methoxy]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N)C(OCC=2C=CC(Cl)=CC=2)=C1 TXPABVKEIGUXHT-UHFFFAOYSA-N 0.000 claims description 2
- NQIKQFMMLZRORL-UHFFFAOYSA-N 5-(6-aminopyridin-3-yl)-3-phenylmethoxypyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CN=C(N)C(OCC=2C=CC=CC=2)=C1 NQIKQFMMLZRORL-UHFFFAOYSA-N 0.000 claims description 2
- RZABWHOYRKZYRO-UHFFFAOYSA-N 5-[3,5-bis(trifluoromethyl)phenyl]-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RZABWHOYRKZYRO-UHFFFAOYSA-N 0.000 claims description 2
- PPQWXUDVNXCERT-UHFFFAOYSA-N 5-[4-(2-morpholin-4-ylethoxy)phenyl]-3-(naphthalen-1-ylmethoxy)pyridin-2-amine Chemical compound C1=C(OCC=2C3=CC=CC=C3C=CC=2)C(N)=NC=C1C(C=C1)=CC=C1OCCN1CCOCC1 PPQWXUDVNXCERT-UHFFFAOYSA-N 0.000 claims description 2
- GFZPBJHWXFUZJG-UHFFFAOYSA-N 5-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]-n-(2-morpholin-4-ylethyl)thiophene-2-carboxamide Chemical compound NC1=NC=C(C=2SC(=CC=2)C(=O)NCCN2CCOCC2)N=C1OCC1=C(F)C=CC(F)=C1Cl GFZPBJHWXFUZJG-UHFFFAOYSA-N 0.000 claims description 2
- RNCJFBCCXMRTPH-UHFFFAOYSA-N 5-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]thiophene-2-carboxylic acid Chemical compound NC1=NC=C(C=2SC(=CC=2)C(O)=O)N=C1OCC1=C(F)C=CC(F)=C1Cl RNCJFBCCXMRTPH-UHFFFAOYSA-N 0.000 claims description 2
- NYAFAHPWSFPXGO-UHFFFAOYSA-N 5-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-2-fluorobenzonitrile Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(F)C(C#N)=C1 NYAFAHPWSFPXGO-UHFFFAOYSA-N 0.000 claims description 2
- BGKHIWPMZAHDGV-UHFFFAOYSA-N 5-[[(1-benzylpyrrolidin-3-yl)amino]methyl]-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1CNC(C1)CCN1CC1=CC=CC=C1 BGKHIWPMZAHDGV-UHFFFAOYSA-N 0.000 claims description 2
- MKSPAJNRSXRKBQ-UHFFFAOYSA-N 5-bromo-3-[(3-fluoro-2-methoxyphenyl)methoxy]pyridin-2-amine Chemical compound COC1=C(F)C=CC=C1COC1=CC(Br)=CN=C1N MKSPAJNRSXRKBQ-UHFFFAOYSA-N 0.000 claims description 2
- ABNOEQPMNIDIFT-UHFFFAOYSA-N 5-bromo-3-[(3-fluoro-2-propan-2-yloxyphenyl)methoxy]pyridin-2-amine Chemical compound CC(C)OC1=C(F)C=CC=C1COC1=CC(Br)=CN=C1N ABNOEQPMNIDIFT-UHFFFAOYSA-N 0.000 claims description 2
- QRGMTTOFGLNJNL-UHFFFAOYSA-N 5-bromo-3-[(3-fluoro-6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-yl)oxy]pyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1OC1C2=CC(F)=CC=C2CCCC1 QRGMTTOFGLNJNL-UHFFFAOYSA-N 0.000 claims description 2
- PXBMWJMUXWMOOF-UHFFFAOYSA-N 5-bromo-3-[1-(2-chloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound C=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(Br)=CN=C1N PXBMWJMUXWMOOF-UHFFFAOYSA-N 0.000 claims description 2
- MPADIFDIHCVNKV-UHFFFAOYSA-N 5-bromo-3-[1-(3-fluoro-2-methoxyphenyl)ethoxy]pyridin-2-amine Chemical compound COC1=C(F)C=CC=C1C(C)OC1=CC(Br)=CN=C1N MPADIFDIHCVNKV-UHFFFAOYSA-N 0.000 claims description 2
- YZYDHYJQVZKHEM-UHFFFAOYSA-N 5-butoxy-3-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-2-amine Chemical compound CCCCOC1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2F)Cl)=C1 YZYDHYJQVZKHEM-UHFFFAOYSA-N 0.000 claims description 2
- KTBINLVGPOBPNR-UHFFFAOYSA-N 5-phenyl-3-[(2,3,6-trifluorophenyl)methoxy]pyridin-2-amine Chemical compound NC1=NC=C(C=2C=CC=CC=2)C=C1OCC1=C(F)C=CC(F)=C1F KTBINLVGPOBPNR-UHFFFAOYSA-N 0.000 claims description 2
- FZKIUUSIEGIYKT-UHFFFAOYSA-N 6-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-1-methylindazole-3-carboxamide Chemical compound C=1C(C=2C=C3N(C)N=C(C3=CC=2)C(N)=O)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl FZKIUUSIEGIYKT-UHFFFAOYSA-N 0.000 claims description 2
- WTBWWJGLPYHIEH-UHFFFAOYSA-N 6-amino-5-[1-(2,6-dichloro-3-cyanophenyl)ethoxy]pyridine-3-carbonitrile Chemical compound ClC=1C=CC(C#N)=C(Cl)C=1C(C)OC1=CC(C#N)=CN=C1N WTBWWJGLPYHIEH-UHFFFAOYSA-N 0.000 claims description 2
- VIGFRDNZWPHYHT-UHFFFAOYSA-N 6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridine-3-carbonitrile Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#N)=CN=C1N VIGFRDNZWPHYHT-UHFFFAOYSA-N 0.000 claims description 2
- VWXDAOMXOJNFLX-UHFFFAOYSA-N 6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-ol Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(O)=CN=C1N VWXDAOMXOJNFLX-UHFFFAOYSA-N 0.000 claims description 2
- DTFPBZXTGBSYPW-UHFFFAOYSA-N 7-[4-(3,5-dimethylpiperazine-1-carbonyl)phenyl]-2-phenyl-4h-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C3OC(C(=O)NC3=NC=2)C=2C=CC=CC=2)C=C1 DTFPBZXTGBSYPW-UHFFFAOYSA-N 0.000 claims description 2
- VRBHUWSSDDCNLV-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NC1(CCN(CC1)CC1=CC=CC=C1)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N Chemical compound C(C1=CC=CC=C1)(=O)NC1(CCN(CC1)CC1=CC=CC=C1)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N VRBHUWSSDDCNLV-UHFFFAOYSA-N 0.000 claims description 2
- PMTDWVPHHCFMFZ-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NCCC1=CC(=C(C=C1)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N)O Chemical compound C(C1=CC=CC=C1)(=O)NCCC1=CC(=C(C=C1)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N)O PMTDWVPHHCFMFZ-UHFFFAOYSA-N 0.000 claims description 2
- KNMQPKQJAAHHGZ-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=C(C=C1)C2=CN=C(C(=N2)OC(C)C3=C(C=CC(=C3Cl)F)Cl)N Chemical compound CCS(=O)(=O)NC1=CC=C(C=C1)C2=CN=C(C(=N2)OC(C)C3=C(C=CC(=C3Cl)F)Cl)N KNMQPKQJAAHHGZ-UHFFFAOYSA-N 0.000 claims description 2
- BLEIGEDAVXUBEA-UHFFFAOYSA-N ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(N)C=C1 Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(N)C=C1 BLEIGEDAVXUBEA-UHFFFAOYSA-N 0.000 claims description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 2
- NHHZKXIBIKIKMO-UHFFFAOYSA-N N-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 NHHZKXIBIKIKMO-UHFFFAOYSA-N 0.000 claims description 2
- JFSVPIDIULVDQQ-UHFFFAOYSA-N N-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 JFSVPIDIULVDQQ-UHFFFAOYSA-N 0.000 claims description 2
- HHMDGNUPNLLSKL-UHFFFAOYSA-N [2-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-4-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(N=CC=1)=CC=1C(=O)N1CCN(C)CC1 HHMDGNUPNLLSKL-UHFFFAOYSA-N 0.000 claims description 2
- UKXPTPMOZOVUOL-UHFFFAOYSA-N [2-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]methanol Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC=C1CO UKXPTPMOZOVUOL-UHFFFAOYSA-N 0.000 claims description 2
- WMSLBRSXPGYZKZ-UHFFFAOYSA-N [3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 WMSLBRSXPGYZKZ-UHFFFAOYSA-N 0.000 claims description 2
- QUDKNHMGJFQVBG-UHFFFAOYSA-N [3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1N1CCCC1 QUDKNHMGJFQVBG-UHFFFAOYSA-N 0.000 claims description 2
- DHQCDCMHAYULMK-UHFFFAOYSA-N [3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-[4-(cyclopropylamino)piperidin-1-yl]methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1NC1CC1 DHQCDCMHAYULMK-UHFFFAOYSA-N 0.000 claims description 2
- LSQMGGSDIJYTIZ-UHFFFAOYSA-N [3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 LSQMGGSDIJYTIZ-UHFFFAOYSA-N 0.000 claims description 2
- SNZVYQKLPGTZLQ-UHFFFAOYSA-N [3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1N1CCCC1 SNZVYQKLPGTZLQ-UHFFFAOYSA-N 0.000 claims description 2
- LXZLKOHQORCVBG-UHFFFAOYSA-N [3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 LXZLKOHQORCVBG-UHFFFAOYSA-N 0.000 claims description 2
- RCTKNLJLGCDXFZ-UHFFFAOYSA-N [3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1N1CCCC1 RCTKNLJLGCDXFZ-UHFFFAOYSA-N 0.000 claims description 2
- CXOARPAHZCTFHX-UHFFFAOYSA-N [3-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3)C(F)(F)F)C(N)=NC=2)=C1 CXOARPAHZCTFHX-UHFFFAOYSA-N 0.000 claims description 2
- FBSWXLMJSBVRQH-UHFFFAOYSA-N [3-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=C(C=CC=2)C(=O)N2CCC(CC2)N2CCCC2)N=C1OCC1=CC=CC(F)=C1C(F)(F)F FBSWXLMJSBVRQH-UHFFFAOYSA-N 0.000 claims description 2
- CQWJGEXEULXQQB-UHFFFAOYSA-N [3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 CQWJGEXEULXQQB-UHFFFAOYSA-N 0.000 claims description 2
- FBLIJTZELJTOSH-UHFFFAOYSA-N [3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-aminopiperidin-1-yl)methanone Chemical compound C1CC(N)CCN1C(=O)C1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 FBLIJTZELJTOSH-UHFFFAOYSA-N 0.000 claims description 2
- CAEYRQHXINZGJK-UHFFFAOYSA-N [3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 CAEYRQHXINZGJK-UHFFFAOYSA-N 0.000 claims description 2
- FQNFURORIUWZRG-UHFFFAOYSA-N [3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]methanol Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(CO)=C1 FQNFURORIUWZRG-UHFFFAOYSA-N 0.000 claims description 2
- WDHNKXHMNWAHSR-UHFFFAOYSA-N [3-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 WDHNKXHMNWAHSR-UHFFFAOYSA-N 0.000 claims description 2
- QJQSIADNHSMFPN-UHFFFAOYSA-N [3-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 QJQSIADNHSMFPN-UHFFFAOYSA-N 0.000 claims description 2
- UVBCTMGXAWIUCG-UHFFFAOYSA-N [4-(6-amino-5-phenylmethoxypyridin-3-yl)phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C=CC=CC=3)C(N)=NC=2)C=C1 UVBCTMGXAWIUCG-UHFFFAOYSA-N 0.000 claims description 2
- XQMMXRNZDXAVRE-UHFFFAOYSA-N [4-(6-amino-5-phenylmethoxypyridin-3-yl)phenyl]-(4-ethylpiperazin-1-yl)methanone Chemical compound C1CN(CC)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C=CC=CC=3)C(N)=NC=2)C=C1 XQMMXRNZDXAVRE-UHFFFAOYSA-N 0.000 claims description 2
- JRCILYMTZPSJQS-UHFFFAOYSA-N [4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 JRCILYMTZPSJQS-UHFFFAOYSA-N 0.000 claims description 2
- WASOVOHUGKCSCW-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 WASOVOHUGKCSCW-UHFFFAOYSA-N 0.000 claims description 2
- KORDDKAJGCSZEW-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 KORDDKAJGCSZEW-UHFFFAOYSA-N 0.000 claims description 2
- BQKSTOOQRYVIRH-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-[4-(cyclopropylamino)piperidin-1-yl]methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1NC1CC1 BQKSTOOQRYVIRH-UHFFFAOYSA-N 0.000 claims description 2
- VYUSJOHXURFLCW-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=NC=1C(=O)N1CCN(C)CC1 VYUSJOHXURFLCW-UHFFFAOYSA-N 0.000 claims description 2
- PSYYECZBGYXYGV-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 PSYYECZBGYXYGV-UHFFFAOYSA-N 0.000 claims description 2
- UIUDVWLKLLITRL-UHFFFAOYSA-N [4-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 UIUDVWLKLLITRL-UHFFFAOYSA-N 0.000 claims description 2
- DUVZYOINSBFADI-UHFFFAOYSA-N [4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 DUVZYOINSBFADI-UHFFFAOYSA-N 0.000 claims description 2
- ZGMVUAVFZJKNEW-UHFFFAOYSA-N [4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 ZGMVUAVFZJKNEW-UHFFFAOYSA-N 0.000 claims description 2
- QHYJSQQUMNBASW-UHFFFAOYSA-N [4-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)N=C1OCC1=CC=CC(F)=C1C(F)(F)F QHYJSQQUMNBASW-UHFFFAOYSA-N 0.000 claims description 2
- PDVBXPVCRVLNPG-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-cyclopropylpiperazin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C2CC2)C=C1OCC1=C(Cl)C=CC=C1Cl PDVBXPVCRVLNPG-UHFFFAOYSA-N 0.000 claims description 2
- DBHGHGBVQVADRC-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)C=C1 DBHGHGBVQVADRC-UHFFFAOYSA-N 0.000 claims description 2
- IYPUXNONGFNQSF-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=C(Cl)C=CC=C1Cl IYPUXNONGFNQSF-UHFFFAOYSA-N 0.000 claims description 2
- RSFKDYSOUXZVQW-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-[4-(2-hydroxyethyl)piperidin-1-yl]methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CCO)CC2)C=C1OCC1=C(Cl)C=CC=C1Cl RSFKDYSOUXZVQW-UHFFFAOYSA-N 0.000 claims description 2
- KYWAICZFDNAJLJ-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]methanol Chemical compound NC1=NC=C(C=2C=CC(CO)=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl KYWAICZFDNAJLJ-UHFFFAOYSA-N 0.000 claims description 2
- UCHNAKVAQLPLQV-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3F)F)C(N)=NC=2)C=C1 UCHNAKVAQLPLQV-UHFFFAOYSA-N 0.000 claims description 2
- WIKQKPRCCMAFDF-UHFFFAOYSA-N [4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 WIKQKPRCCMAFDF-UHFFFAOYSA-N 0.000 claims description 2
- KLBJMOIJISVJBZ-UHFFFAOYSA-N [4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-aminopiperidin-1-yl)methanone Chemical compound C1CC(N)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 KLBJMOIJISVJBZ-UHFFFAOYSA-N 0.000 claims description 2
- AHOPXZBBGBTORE-UHFFFAOYSA-N [4-[6-amino-5-[(2-chloro-4-fluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC(F)=CC=3)Cl)C(N)=NC=2)C=C1 AHOPXZBBGBTORE-UHFFFAOYSA-N 0.000 claims description 2
- CIRAQVLTXSCTHW-UHFFFAOYSA-N [4-[6-amino-5-[(4-tert-butylphenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C=CC(=CC=3)C(C)(C)C)C(N)=NC=2)C=C1 CIRAQVLTXSCTHW-UHFFFAOYSA-N 0.000 claims description 2
- XKNINUBHMGWYIV-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-2-fluorophenyl]-(2,2-dimethylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1F)=CC=C1C(=O)N1CCNCC1(C)C XKNINUBHMGWYIV-UHFFFAOYSA-N 0.000 claims description 2
- UMPYPHGQYLPPCA-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-3,5-dimethoxyphenyl]-(2,2-dimethylpiperazin-1-yl)methanone Chemical compound COC1=CC(C(=O)N2C(CNCC2)(C)C)=CC(OC)=C1C(C=1)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl UMPYPHGQYLPPCA-UHFFFAOYSA-N 0.000 claims description 2
- XVBOYOUFSVIWSH-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-3-methylphenyl]-(2,2-dimethylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C(=C1)C)=CC=C1C(=O)N1CCNCC1(C)C XVBOYOUFSVIWSH-UHFFFAOYSA-N 0.000 claims description 2
- GCAWDBGSEXDBIP-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(1,4-diazepan-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCCNCC1 GCAWDBGSEXDBIP-UHFFFAOYSA-N 0.000 claims description 2
- KOOGZNWWYRPBFJ-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 KOOGZNWWYRPBFJ-UHFFFAOYSA-N 0.000 claims description 2
- GCHXQZRZNXAOKV-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methyl-1,4-diazepan-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCCN(C)CC1 GCHXQZRZNXAOKV-UHFFFAOYSA-N 0.000 claims description 2
- QKKQTHMHWWMDSY-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 QKKQTHMHWWMDSY-UHFFFAOYSA-N 0.000 claims description 2
- XHGZJBSXOKTZEU-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-morpholin-4-ylmethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCOCC1 XHGZJBSXOKTZEU-UHFFFAOYSA-N 0.000 claims description 2
- IGTXHUMAYCGTDA-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-piperazin-1-ylmethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCNCC1 IGTXHUMAYCGTDA-UHFFFAOYSA-N 0.000 claims description 2
- XGSWRRJHRXEUHF-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-piperidin-1-ylmethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCCCC1 XGSWRRJHRXEUHF-UHFFFAOYSA-N 0.000 claims description 2
- KBQPDFCLFIMCLM-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-pyrrolidin-1-ylmethanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCCC1 KBQPDFCLFIMCLM-UHFFFAOYSA-N 0.000 claims description 2
- OWJYVAGQUFLWBE-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 OWJYVAGQUFLWBE-UHFFFAOYSA-N 0.000 claims description 2
- CDAABCUOKXSPJC-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 CDAABCUOKXSPJC-UHFFFAOYSA-N 0.000 claims description 2
- GDNMBLFQCIKWSG-UHFFFAOYSA-N [4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-ethylpiperazin-1-yl)methanone Chemical compound C1CN(CC)CCN1C(=O)C1=CC=C(C=2C=C(OC(C)C=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 GDNMBLFQCIKWSG-UHFFFAOYSA-N 0.000 claims description 2
- ZQAQQCXBCQPQOX-UHFFFAOYSA-N [4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ZQAQQCXBCQPQOX-UHFFFAOYSA-N 0.000 claims description 2
- HGTBKRYDMKQWBN-UHFFFAOYSA-N [4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 HGTBKRYDMKQWBN-UHFFFAOYSA-N 0.000 claims description 2
- QTKJXYDBTIWDAC-UHFFFAOYSA-N [4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=NC=1C(=O)N1CCN(C)CC1 QTKJXYDBTIWDAC-UHFFFAOYSA-N 0.000 claims description 2
- NLSGGEDXODSKPV-UHFFFAOYSA-N [4-[6-amino-5-[1-[2-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 NLSGGEDXODSKPV-UHFFFAOYSA-N 0.000 claims description 2
- WLBBAKVPDWTROC-UHFFFAOYSA-N [4-[6-amino-5-[1-[3-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 WLBBAKVPDWTROC-UHFFFAOYSA-N 0.000 claims description 2
- GSTGRNHIGZKLTR-UHFFFAOYSA-N [4-[6-amino-5-[1-[3-fluoro-2-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C=CC(F)=C(C(F)(F)F)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 GSTGRNHIGZKLTR-UHFFFAOYSA-N 0.000 claims description 2
- GMQINZXTXZUSGP-UHFFFAOYSA-N [4-[6-amino-5-[[2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 GMQINZXTXZUSGP-UHFFFAOYSA-N 0.000 claims description 2
- HHLJBWJBMWNGOP-UHFFFAOYSA-N [4-[6-amino-5-[[2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=CC=C1C(F)(F)F HHLJBWJBMWNGOP-UHFFFAOYSA-N 0.000 claims description 2
- JMFREZMQIYMKAO-UHFFFAOYSA-N [4-[6-amino-5-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 JMFREZMQIYMKAO-UHFFFAOYSA-N 0.000 claims description 2
- QKNTVQVVZBGJGN-UHFFFAOYSA-N [4-[6-amino-5-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=CC(F)=C1C(F)(F)F QKNTVQVVZBGJGN-UHFFFAOYSA-N 0.000 claims description 2
- GFOGAKOOQFXPTC-UHFFFAOYSA-N [4-[6-amino-5-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyridin-3-yl]phenyl]-[3-(dimethylamino)pyrrolidin-1-yl]methanone Chemical compound C1C(N(C)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 GFOGAKOOQFXPTC-UHFFFAOYSA-N 0.000 claims description 2
- FINPBYRDTVSMRZ-UHFFFAOYSA-N [5-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]thiophen-2-yl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2SC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)N=C1OCC1=C(F)C=CC(F)=C1Cl FINPBYRDTVSMRZ-UHFFFAOYSA-N 0.000 claims description 2
- LGGUYGOKKTVPCH-UHFFFAOYSA-N [5-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CN=CC=1C(=O)N1CCN(C)CC1 LGGUYGOKKTVPCH-UHFFFAOYSA-N 0.000 claims description 2
- ZURQXWIYRKRKHN-UHFFFAOYSA-N [5-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]thiophen-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)S1 ZURQXWIYRKRKHN-UHFFFAOYSA-N 0.000 claims description 2
- FQXVPKZLKKFLLQ-UHFFFAOYSA-N [5-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]thiophen-2-yl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2SC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=C(F)C=CC(F)=C1Cl FQXVPKZLKKFLLQ-UHFFFAOYSA-N 0.000 claims description 2
- KYBBGWCVQUTRDW-UHFFFAOYSA-N [5-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CN=CC=1C(=O)N1CCN(C)CC1 KYBBGWCVQUTRDW-UHFFFAOYSA-N 0.000 claims description 2
- MOFORHKMXAUGMV-UHFFFAOYSA-N [5-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=N1)=CC=C1C(=O)N1CCN(C)CC1 MOFORHKMXAUGMV-UHFFFAOYSA-N 0.000 claims description 2
- PZJSFGFQDYOEDD-UHFFFAOYSA-N [6-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(N=1)=CC=CC=1C(=O)N1CCN(C)CC1 PZJSFGFQDYOEDD-UHFFFAOYSA-N 0.000 claims description 2
- DXJDJFDHQSGWOY-UHFFFAOYSA-N [6-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(N=C1)=CC=C1C(=O)N1CCN(C)CC1 DXJDJFDHQSGWOY-UHFFFAOYSA-N 0.000 claims description 2
- UIVFGHYSQQNWFN-UHFFFAOYSA-N [6-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(N=C1)=CC=C1C(=O)N1CCN(C)CC1 UIVFGHYSQQNWFN-UHFFFAOYSA-N 0.000 claims description 2
- SKLSFPPQMIPPEZ-UHFFFAOYSA-N [6-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C1=CC=C(C=2N=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)N=C1 SKLSFPPQMIPPEZ-UHFFFAOYSA-N 0.000 claims description 2
- UGCAPERLWHYSIC-UHFFFAOYSA-N [6-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]pyridin-2-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(N=1)=CC=CC=1C(=O)N1CCN(C)CC1 UGCAPERLWHYSIC-UHFFFAOYSA-N 0.000 claims description 2
- JJGANHPZLZTDGT-UHFFFAOYSA-N [6-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(N=C1)=CC=C1C(=O)N1CCN(C)CC1 JJGANHPZLZTDGT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002723 alicyclic group Chemical group 0.000 claims description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 2
- FCOFUDRGQXLVKL-UHFFFAOYSA-N ethyl 2-[4-[6-amino-5-[(2,6-difluorophenyl)methoxy]pyridin-3-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1C1=CN=C(N)C(OCC=2C(=CC=CC=2F)F)=C1 FCOFUDRGQXLVKL-UHFFFAOYSA-N 0.000 claims description 2
- CBLZKOARTGRECJ-UHFFFAOYSA-N ethyl 5-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]-1h-indole-2-carboxylate Chemical compound C=1C=C2NC(C(=O)OCC)=CC2=CC=1C(C=1)=CN=C(N)C=1OCC1=C(Cl)C=CC=C1Cl CBLZKOARTGRECJ-UHFFFAOYSA-N 0.000 claims description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
- ICDGQBSINVDDNH-UHFFFAOYSA-N methyl 2-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 ICDGQBSINVDDNH-UHFFFAOYSA-N 0.000 claims description 2
- UEGIWWILYKXDGR-UHFFFAOYSA-N methyl 3-[[2-amino-5-[4-(3,5-dimethylpiperazine-1-carbonyl)phenyl]pyridin-3-yl]oxymethyl]benzoate Chemical compound COC(=O)C1=CC=CC(COC=2C(=NC=C(C=2)C=2C=CC(=CC=2)C(=O)N2CC(C)NC(C)C2)N)=C1 UEGIWWILYKXDGR-UHFFFAOYSA-N 0.000 claims description 2
- ARGHYNJBPLSKRW-UHFFFAOYSA-N methyl 4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-3-methylbenzoate Chemical compound CC1=CC(C(=O)OC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=C1 ARGHYNJBPLSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- IAMPDRRVWOQHHR-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCNC3CC3)C=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl IAMPDRRVWOQHHR-UHFFFAOYSA-N 0.000 claims description 2
- CJHGLAARFIMKNY-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(cyclopropylmethylamino)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCNCC3CC3)C=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl CJHGLAARFIMKNY-UHFFFAOYSA-N 0.000 claims description 2
- FRJNLEFOROHHPZ-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(diethylamino)ethanesulfonamide Chemical compound CCN(CC)CCS(=O)(=O)NC1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 FRJNLEFOROHHPZ-UHFFFAOYSA-N 0.000 claims description 2
- WLKCNQKSMUQWMY-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound CN(C)CCS(=O)(=O)NC1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 WLKCNQKSMUQWMY-UHFFFAOYSA-N 0.000 claims description 2
- IWHAZWQZFQZWPD-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCN(CC3)C(=O)CO)C=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl IWHAZWQZFQZWPD-UHFFFAOYSA-N 0.000 claims description 2
- CNGUDOJBIWSGSB-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-pyrrolidin-1-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCCC3)C=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl CNGUDOJBIWSGSB-UHFFFAOYSA-N 0.000 claims description 2
- RZVTYDFOUPUICN-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(diethylamino)ethanesulfonamide Chemical compound CCN(CC)CCS(=O)(=O)NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 RZVTYDFOUPUICN-UHFFFAOYSA-N 0.000 claims description 2
- ZCBIWSPFLPWAQV-UHFFFAOYSA-N n-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-4-methylpiperazine-1-carboxamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)N1CCN(C)CC1 ZCBIWSPFLPWAQV-UHFFFAOYSA-N 0.000 claims description 2
- PKSBAWQOPGQPLS-UHFFFAOYSA-N n-[3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynyl]-4-pyrrolidin-1-ylpiperidine-1-carboxamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CCNC(=O)N(CC1)CCC1N1CCCC1 PKSBAWQOPGQPLS-UHFFFAOYSA-N 0.000 claims description 2
- SFJRXAIQIZRNJC-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(4-hydroxypiperidin-1-yl)ethanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCC(O)CC1 SFJRXAIQIZRNJC-UHFFFAOYSA-N 0.000 claims description 2
- XYTQSLMCOXKNSC-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(diethylamino)ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(CC)CC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2Cl)Cl)=N1 XYTQSLMCOXKNSC-UHFFFAOYSA-N 0.000 claims description 2
- IHGRHDPOLIBBDA-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 IHGRHDPOLIBBDA-UHFFFAOYSA-N 0.000 claims description 2
- PKXYROSEXPOAIM-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-pyrrolidin-1-ylethanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCCC1 PKXYROSEXPOAIM-UHFFFAOYSA-N 0.000 claims description 2
- YYNPDXVSPZDOMQ-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)N1CCN(C)CC1 YYNPDXVSPZDOMQ-UHFFFAOYSA-N 0.000 claims description 2
- SQUICNYYYZBLJC-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCN(C(=O)CO)CC1 SQUICNYYYZBLJC-UHFFFAOYSA-N 0.000 claims description 2
- BDRVEAGDBLTXCK-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NC(=O)N1CCN(C)CC1 BDRVEAGDBLTXCK-UHFFFAOYSA-N 0.000 claims description 2
- VQTOUEXUOHWPAX-UHFFFAOYSA-N n-[4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(diethylamino)ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(CC)CC)=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=C1 VQTOUEXUOHWPAX-UHFFFAOYSA-N 0.000 claims description 2
- SWGQPFCOSUGUSZ-UHFFFAOYSA-N n-[4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(C)C)=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=C1 SWGQPFCOSUGUSZ-UHFFFAOYSA-N 0.000 claims description 2
- HJLYJIKFIXFFNO-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NS(=O)(=O)CCNC1CC1 HJLYJIKFIXFFNO-UHFFFAOYSA-N 0.000 claims description 2
- AJPNUMSKDNRFPP-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 AJPNUMSKDNRFPP-UHFFFAOYSA-N 0.000 claims description 2
- HQZUNIRPYOCGFK-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)N1CCN(C)CC1 HQZUNIRPYOCGFK-UHFFFAOYSA-N 0.000 claims description 2
- UPJXWEBRVSCUBN-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-4-methylpiperazine-1-carboxamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NC(=O)N1CCN(C)CC1 UPJXWEBRVSCUBN-UHFFFAOYSA-N 0.000 claims description 2
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 3
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- NNLODUQKKTYGMP-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 Chemical compound CCS(=O)(=O)NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 NNLODUQKKTYGMP-UHFFFAOYSA-N 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- LFUSLRNGJLCMKH-UHFFFAOYSA-N 1-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-2-methylbut-3-yn-2-yl]-3-(2-pyrrolidin-1-ylethyl)urea Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CC(C)(C)NC(=O)NCCN1CCCC1 LFUSLRNGJLCMKH-UHFFFAOYSA-N 0.000 claims 1
- BTGNLYUOHYOJKM-UHFFFAOYSA-N 2-(4-hydroxypiperidin-1-yl)ethanesulfonic acid Chemical compound OC1CCN(CCS(O)(=O)=O)CC1 BTGNLYUOHYOJKM-UHFFFAOYSA-N 0.000 claims 1
- KTZFIQVZRIPKSY-UHFFFAOYSA-N 2-(cyclopropylmethylamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNCC1CC1 KTZFIQVZRIPKSY-UHFFFAOYSA-N 0.000 claims 1
- YIAGRWLFJWTYTD-UHFFFAOYSA-N 3,5-dimethylpiperazine-1-carbaldehyde Chemical compound CC1CN(C=O)CC(C)N1 YIAGRWLFJWTYTD-UHFFFAOYSA-N 0.000 claims 1
- FMGAYBVWLXVTPO-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[3-(dimethylamino)prop-1-ynyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CCN(C)C)=CN=C1N FMGAYBVWLXVTPO-UHFFFAOYSA-N 0.000 claims 1
- JSAOORPOJFXWQY-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NC1CCN(C)CC1 JSAOORPOJFXWQY-UHFFFAOYSA-N 0.000 claims 1
- ZJGYSLJXSPUTCK-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCCN1CCCC1 ZJGYSLJXSPUTCK-UHFFFAOYSA-N 0.000 claims 1
- ZERPVRWXDUAJKA-UHFFFAOYSA-N 3-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)NC1CCN(C)CC1 ZERPVRWXDUAJKA-UHFFFAOYSA-N 0.000 claims 1
- AYRJWQOTKREUBZ-UHFFFAOYSA-N 3-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)NCCCN1CCCC1 AYRJWQOTKREUBZ-UHFFFAOYSA-N 0.000 claims 1
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 claims 1
- DYCFNCARNPWXNS-UHFFFAOYSA-N 4-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)NCCCN1CCCC1 DYCFNCARNPWXNS-UHFFFAOYSA-N 0.000 claims 1
- XBJFDURAPHYGEG-UHFFFAOYSA-N 4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)NC1CCN(C)CC1 XBJFDURAPHYGEG-UHFFFAOYSA-N 0.000 claims 1
- NHQWTJPNEZPWOY-UHFFFAOYSA-N 4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)NCCCN1CCCC1 NHQWTJPNEZPWOY-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- YJKSBHPLLPUPHG-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCC1N1CCCC1 YJKSBHPLLPUPHG-UHFFFAOYSA-N 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- FNKNWCOTVVFELA-UHFFFAOYSA-N NC1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 Chemical compound NC1=CC=CC(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 FNKNWCOTVVFELA-UHFFFAOYSA-N 0.000 claims 1
- LPWNBBNZNCSNBM-UHFFFAOYSA-N [3-[6-amino-5-[1-(2,6-dichlorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)N(CC1)CCC1N1CCCC1 LPWNBBNZNCSNBM-UHFFFAOYSA-N 0.000 claims 1
- KKZCMUIQONHMRX-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-3-fluorophenyl]-(2,2-dimethylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C(=C1)F)=CC=C1C(=O)N1CCNCC1(C)C KKZCMUIQONHMRX-UHFFFAOYSA-N 0.000 claims 1
- TZKWGQKDGVTSAV-UHFFFAOYSA-N [4-[6-amino-5-[1-[3-fluoro-2-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C=1C=CC(F)=C(C(F)(F)F)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCN(C)CC1 TZKWGQKDGVTSAV-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- CFAFEJHONLMPQY-UHFFFAOYSA-N beta-Dimethylamino-aethan-alpha-sulfonsaeure Natural products CN(C)CCS(O)(=O)=O CFAFEJHONLMPQY-UHFFFAOYSA-N 0.000 claims 1
- ZTISWCXLXLMLLY-UHFFFAOYSA-N n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NCCN1CCCC1 ZTISWCXLXLMLLY-UHFFFAOYSA-N 0.000 claims 1
- RIEFAMQPKMRBNR-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-3-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]benzamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCN1CCN(C(C)=O)CC1 RIEFAMQPKMRBNR-UHFFFAOYSA-N 0.000 claims 1
- LMHYKNSVVMYMSK-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-4-[5-amino-6-[1-(2,6-dichlorophenyl)ethoxy]pyrazin-2-yl]benzamide Chemical compound ClC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)NCCN1CCN(C(C)=O)CC1 LMHYKNSVVMYMSK-UHFFFAOYSA-N 0.000 claims 1
- BJCHVXIFOQTLEN-UHFFFAOYSA-N n-[3-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-morpholin-4-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCOCC3)C=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl BJCHVXIFOQTLEN-UHFFFAOYSA-N 0.000 claims 1
- JDISLXKDNWALRM-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(4-hydroxypiperidin-1-yl)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCC(O)CC3)C=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl JDISLXKDNWALRM-UHFFFAOYSA-N 0.000 claims 1
- JKKIWRSWPUITDL-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCNC3CC3)C=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl JKKIWRSWPUITDL-UHFFFAOYSA-N 0.000 claims 1
- ZKHWNVXAJDRILZ-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(cyclopropylmethylamino)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCNCC3CC3)C=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl ZKHWNVXAJDRILZ-UHFFFAOYSA-N 0.000 claims 1
- KFVMVJSVVXWSAB-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCN(CC3)C(=O)CO)C=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl KFVMVJSVVXWSAB-UHFFFAOYSA-N 0.000 claims 1
- WGOTWVZKYLVAES-UHFFFAOYSA-N n-[4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound NC1=NC=C(C=2C=CC(NS(=O)(=O)CCNC3CC3)=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl WGOTWVZKYLVAES-UHFFFAOYSA-N 0.000 claims 1
- TVIUISDOAYHBJU-UHFFFAOYSA-N n-[4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-(diethylamino)ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(CC)CC)=CC=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=N1 TVIUISDOAYHBJU-UHFFFAOYSA-N 0.000 claims 1
- UUOTXIDKQUZDJO-UHFFFAOYSA-N n-[4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethanesulfonamide Chemical compound NC1=NC=C(C=2C=CC(NS(=O)(=O)CCN3CCN(CC3)C(=O)CO)=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl UUOTXIDKQUZDJO-UHFFFAOYSA-N 0.000 claims 1
- SVSGDZBMYJKARV-UHFFFAOYSA-N n-[4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-2-piperidin-1-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=CC(NS(=O)(=O)CCN3CCCCC3)=CC=2)N=C1OCC1=C(F)C=CC(F)=C1Cl SVSGDZBMYJKARV-UHFFFAOYSA-N 0.000 claims 1
- RGUGOKJGDJZBBA-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(4-hydroxypiperidin-1-yl)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCC(O)CC1 RGUGOKJGDJZBBA-UHFFFAOYSA-N 0.000 claims 1
- VPEKFZMGWMRBKD-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCNC1CC1 VPEKFZMGWMRBKD-UHFFFAOYSA-N 0.000 claims 1
- SWCPJNTXETZBOD-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-(cyclopropylmethylamino)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCNCC1CC1 SWCPJNTXETZBOD-UHFFFAOYSA-N 0.000 claims 1
- ASEPRWGQDDTXTL-UHFFFAOYSA-N n-[4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-2-pyrrolidin-1-ylethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCCC1 ASEPRWGQDDTXTL-UHFFFAOYSA-N 0.000 claims 1
- OKTLFSAUOGDLQE-UHFFFAOYSA-N n-[4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-morpholin-4-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=CC(NS(=O)(=O)CCN3CCOCC3)=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl OKTLFSAUOGDLQE-UHFFFAOYSA-N 0.000 claims 1
- AVBZEIDPFBBKFL-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]methanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NS(C)(=O)=O)C=C1 AVBZEIDPFBBKFL-UHFFFAOYSA-N 0.000 claims 1
- BPSVKCXMOKSSNF-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-2-(4-hydroxypiperidin-1-yl)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NS(=O)(=O)CCN1CCC(O)CC1 BPSVKCXMOKSSNF-UHFFFAOYSA-N 0.000 claims 1
- RKSYLGKLDWMSMO-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-2-(cyclopropylamino)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1NS(=O)(=O)CCNC1CC1 RKSYLGKLDWMSMO-UHFFFAOYSA-N 0.000 claims 1
- WIMIUXUBCOQODK-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 WIMIUXUBCOQODK-UHFFFAOYSA-N 0.000 claims 1
- NBMOECVWANZLDG-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]phenyl]methanesulfonamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(NS(C)(=O)=O)C=C1 NBMOECVWANZLDG-UHFFFAOYSA-N 0.000 claims 1
- VSILIVLHDLVRKG-UHFFFAOYSA-N n-[[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]methyl]acetamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(CNC(C)=O)=CN=C1N VSILIVLHDLVRKG-UHFFFAOYSA-N 0.000 claims 1
- UQBQXXJRYXJKGK-UHFFFAOYSA-N n-[[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]methyl]methanesulfonamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(CNS(C)(=O)=O)=CN=C1N UQBQXXJRYXJKGK-UHFFFAOYSA-N 0.000 claims 1
- FDDQRDMHICUGQC-UHFFFAOYSA-N pyrrole-1-carboxylic acid Chemical compound OC(=O)N1C=CC=C1 FDDQRDMHICUGQC-UHFFFAOYSA-N 0.000 claims 1
- 229940055764 triaz Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 69
- 238000000034 method Methods 0.000 abstract description 67
- 230000000694 effects Effects 0.000 abstract description 33
- 239000003112 inhibitor Substances 0.000 abstract description 22
- 150000003927 aminopyridines Chemical class 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 79
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 59
- 102000001253 Protein Kinase Human genes 0.000 description 58
- 208000035475 disorder Diseases 0.000 description 58
- 108060006633 protein kinase Proteins 0.000 description 58
- 206010028980 Neoplasm Diseases 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 28
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 28
- 230000003197 catalytic effect Effects 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 22
- 150000002431 hydrogen Chemical class 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 20
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- 230000019491 signal transduction Effects 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 230000033115 angiogenesis Effects 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000000546 pharmaceutical excipient Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 101100215673 Arabidopsis thaliana AGL11 gene Proteins 0.000 description 15
- 101150073911 STK gene Proteins 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 230000004862 vasculogenesis Effects 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 108010009202 Growth Factor Receptors Proteins 0.000 description 10
- 102000009465 Growth Factor Receptors Human genes 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000007429 general method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 9
- 230000024245 cell differentiation Effects 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 201000004681 Psoriasis Diseases 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 125000004212 difluorophenyl group Chemical group 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- STWODXDTKGTVCJ-UHFFFAOYSA-N 4-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1C1CCNCC1 STWODXDTKGTVCJ-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 description 5
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 208000014829 head and neck neoplasm Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 210000003584 mesangial cell Anatomy 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- ZFNMAJBVWOHSSF-UHFFFAOYSA-N 5-bromo-3-phenylmethoxypyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1OCC1=CC=CC=C1 ZFNMAJBVWOHSSF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010055325 EphB3 Receptor Proteins 0.000 description 4
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 4
- 101000587820 Homo sapiens Selenide, water dikinase 1 Proteins 0.000 description 4
- 101000701815 Homo sapiens Spermidine synthase Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 102100031163 Selenide, water dikinase 1 Human genes 0.000 description 4
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 238000013127 simulated treatment comparison Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BVOMRRWJQOJMPA-UHFFFAOYSA-N 1,2,3-trithiane Chemical compound C1CSSSC1 BVOMRRWJQOJMPA-UHFFFAOYSA-N 0.000 description 3
- AGMHZPKKMSYUOR-UHFFFAOYSA-N 2-amino-5-phenylpyridin-3-ol Chemical compound C1=C(O)C(N)=NC=C1C1=CC=CC=C1 AGMHZPKKMSYUOR-UHFFFAOYSA-N 0.000 description 3
- SROXKENAXWOWHM-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-iodopyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(I)=CN=C1N SROXKENAXWOWHM-UHFFFAOYSA-N 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 101100327358 Rattus norvegicus Cdk12 gene Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001543 aryl boronic acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- OIMWEHOYHJJPJD-UHFFFAOYSA-N pyridine;pyrimidine Chemical compound C1=CC=NC=C1.C1=CN=CN=C1 OIMWEHOYHJJPJD-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- HBHRVBSRQUCWAJ-UHFFFAOYSA-N 2-(diethylamino)-n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CCN(CC)CC)=CC=C1B1OC(C)(C)C(C)(C)O1 HBHRVBSRQUCWAJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 2
- YQADLKDQAXAIKW-UHFFFAOYSA-N 2-amino-5-bromopyridin-3-ol Chemical compound NC1=NC=C(Br)C=C1O YQADLKDQAXAIKW-UHFFFAOYSA-N 0.000 description 2
- VHCSBTPOPKFYIU-UHFFFAOYSA-N 2-chloroethanesulfonyl chloride Chemical compound ClCCS(Cl)(=O)=O VHCSBTPOPKFYIU-UHFFFAOYSA-N 0.000 description 2
- DTLBKXRFWUERQN-UHFFFAOYSA-N 3,5-dibromopyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Br DTLBKXRFWUERQN-UHFFFAOYSA-N 0.000 description 2
- HFYRBNUFCSNKGE-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-(1h-indol-5-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C=CNC3=CC=2)C=C1OCC1=C(Cl)C=CC=C1Cl HFYRBNUFCSNKGE-UHFFFAOYSA-N 0.000 description 2
- GKWQVTOKMIOGLG-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCCN1CCCC1 GKWQVTOKMIOGLG-UHFFFAOYSA-N 0.000 description 2
- NVPNUJRCUYSBPJ-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]prop-2-ynylcarbamic acid Chemical compound NC1=C(C=C(C=N1)C#CCNC(O)=O)OC(C)C1=C(C(=CC=C1Cl)F)Cl NVPNUJRCUYSBPJ-UHFFFAOYSA-N 0.000 description 2
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 2
- NMLYQARFKGZHJS-UHFFFAOYSA-N 4-[6-amino-5-[1-[3-fluoro-2-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]benzoic acid Chemical compound C=1C=CC(F)=C(C(F)(F)F)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(C(O)=O)C=C1 NMLYQARFKGZHJS-UHFFFAOYSA-N 0.000 description 2
- DITLHAMZSLQMHD-UHFFFAOYSA-N 5-phenyl-2-(tritylamino)pyridin-3-ol Chemical compound OC1=CC(C=2C=CC=CC=2)=CN=C1NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DITLHAMZSLQMHD-UHFFFAOYSA-N 0.000 description 2
- VQPBRWIFFBIRRP-UHFFFAOYSA-N 6-bromo-3h-[1,3]oxazolo[4,5-b]pyridin-2-one Chemical compound BrC1=CN=C2NC(=O)OC2=C1 VQPBRWIFFBIRRP-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 101100273868 Anopheles gambiae CecC gene Proteins 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 101100059604 Ceratitis capitata CEC2 gene Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 2
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229960005552 PAC-1 Drugs 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 201000005746 Pituitary adenoma Diseases 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- IISQAMCWYPTOCU-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(NC(O)=O)C=C1 IISQAMCWYPTOCU-UHFFFAOYSA-N 0.000 description 2
- AUCWHTWWTRFLTK-UHFFFAOYSA-N [4-[6-amino-5-[1-[2-fluoro-6-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound FC=1C=CC=C(C(F)(F)F)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 AUCWHTWWTRFLTK-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- SBIRITMEJGWXBM-UHFFFAOYSA-N methyl 4-(6-amino-5-hydroxypyridin-3-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(N)C(O)=C1 SBIRITMEJGWXBM-UHFFFAOYSA-N 0.000 description 2
- CDORJOSRNOYIDE-UHFFFAOYSA-N methyl 4-[6-amino-5-[1-[3-fluoro-2-(trifluoromethyl)phenyl]ethoxy]pyridin-3-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(N)C(OC(C)C=2C(=C(F)C=CC=2)C(F)(F)F)=C1 CDORJOSRNOYIDE-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- ASFVKOYNTPOQKK-UHFFFAOYSA-N n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=CC=C1 ASFVKOYNTPOQKK-UHFFFAOYSA-N 0.000 description 2
- JTNDORAWCIEWNX-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCCN1CCOCC1 JTNDORAWCIEWNX-UHFFFAOYSA-N 0.000 description 2
- WKRCSVLEBALYIJ-UHFFFAOYSA-N n-(3-morpholin-4-ylpropyl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCCCN1CCOCC1 WKRCSVLEBALYIJ-UHFFFAOYSA-N 0.000 description 2
- SVPDWDHXJAXYFO-UHFFFAOYSA-N n-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1B1OC(C)(C)C(C)(C)O1 SVPDWDHXJAXYFO-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000033667 organ regeneration Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000005504 styryl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 201000011294 ureter cancer Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- UAVZYYMDCMMMSN-UHFFFAOYSA-N (6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]methanone Chemical compound C=1C(C=2C=CC(=CC=2)C(=O)N2CC3C(N)C3C2)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl UAVZYYMDCMMMSN-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FSNGFFWICFYWQC-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine;hydron;chloride Chemical compound Cl.ClCCN1CCCC1 FSNGFFWICFYWQC-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- LNWXALCHPJANMJ-UHFFFAOYSA-N 1-(bromomethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CBr)=C1 LNWXALCHPJANMJ-UHFFFAOYSA-N 0.000 description 1
- KQISQNCCCASSDX-UHFFFAOYSA-N 1-(pyrrolidin-1-ylmethyl)pyrrolidine Chemical compound C1CCCN1CN1CCCC1 KQISQNCCCASSDX-UHFFFAOYSA-N 0.000 description 1
- JQWPMNYISQEDOS-UHFFFAOYSA-N 1-[3-fluoro-2-(trifluoromethyl)phenyl]ethanol Chemical compound CC(O)C1=CC=CC(F)=C1C(F)(F)F JQWPMNYISQEDOS-UHFFFAOYSA-N 0.000 description 1
- LTVIJEFEZVFIST-UHFFFAOYSA-N 1-[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound ONC(=O)C1C(C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1Cl LTVIJEFEZVFIST-UHFFFAOYSA-N 0.000 description 1
- ZHCXOELPVFPGHI-UHFFFAOYSA-N 1-[4-[(4-fluoro-2-methylphenyl)methoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound CC1=CC(F)=CC=C1COC1=CC=C(S(=O)(=O)N2C(C(C)(O)CCC2)C(=O)NO)C=C1 ZHCXOELPVFPGHI-UHFFFAOYSA-N 0.000 description 1
- UMQQWNRAHOAVIM-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[(2,4-dichlorophenyl)methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC(Cl)=CC=3)Cl)C(N)=NC=2)C=C1 UMQQWNRAHOAVIM-UHFFFAOYSA-N 0.000 description 1
- WDXIEYZUDJRHJB-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[(2-chloro-6-fluorophenyl)methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3F)Cl)C(N)=NC=2)C=C1 WDXIEYZUDJRHJB-UHFFFAOYSA-N 0.000 description 1
- ZWXAPRUGWBKJSY-UHFFFAOYSA-N 1-[4-[4-[6-amino-5-[(2-chlorophenyl)methoxy]pyridin-3-yl]benzoyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)Cl)C(N)=NC=2)C=C1 ZWXAPRUGWBKJSY-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QMBIKDNTNNAHDU-UHFFFAOYSA-N 2,2-dimethylpiperazine-1-carbaldehyde Chemical compound CC1(C)CNCCN1C=O QMBIKDNTNNAHDU-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 1
- AJBORVKVKPSGCG-UHFFFAOYSA-N 2-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]pyrrole-1-carboxylic acid Chemical compound NC1=C(C=C(C=N1)C=1N(C=CC=1)C(=O)O)OCC1=C(C=CC=C1Cl)Cl AJBORVKVKPSGCG-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
- ILKFQTMRZZZCLU-UHFFFAOYSA-N 2-amino-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-3-ol Chemical compound C1=C(O)C(N)=NC=C1C(C=C1)=CC=C1OCCN1CCOCC1 ILKFQTMRZZZCLU-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- ZIFJZWXEACSTMH-UHFFFAOYSA-N 2h-benzotriazol-4-ylmethanamine Chemical compound NCC1=CC=CC2=C1N=NN2 ZIFJZWXEACSTMH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- RYCSNJCJOVQGBC-UHFFFAOYSA-N 3-(1-cyclopropyl-2h-pyridin-4-yl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C(C=C1)=CCN1C1CC1 RYCSNJCJOVQGBC-UHFFFAOYSA-N 0.000 description 1
- ZBQUWRHABOYVQK-UHFFFAOYSA-N 3-(3,5-dimethyl-1H-pyrrol-2-yl)-4-methylidene-3,3a-dihydro-1H-indol-2-one Chemical compound CC=1NC(=C(C1)C)C1C(NC2=CC=CC(C12)=C)=O ZBQUWRHABOYVQK-UHFFFAOYSA-N 0.000 description 1
- NMCBWICNRJLKKM-UHFFFAOYSA-N 3-(benzyloxy)pyridin-2-amine Chemical compound NC1=NC=CC=C1OCC1=CC=CC=C1 NMCBWICNRJLKKM-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FOAFVAWHNNFMLI-UHFFFAOYSA-N 3-[(2,6-dichloro-3-fluorophenyl)methoxy]-5-(1,3-thiazol-2-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2SC=CN=2)C=C1OCC1=C(Cl)C=CC(F)=C1Cl FOAFVAWHNNFMLI-UHFFFAOYSA-N 0.000 description 1
- SMLCMTLZQFHFFR-UHFFFAOYSA-N 3-[(2,6-dichloro-3-fluorophenyl)methoxy]-5-(1-methylimidazol-2-yl)pyridin-2-amine Chemical compound CN1C=CN=C1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2Cl)Cl)=C1 SMLCMTLZQFHFFR-UHFFFAOYSA-N 0.000 description 1
- WPEGHYKGSUIDLP-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]pyridin-2-amine Chemical compound C1CN(C)CCC1C1=CNC2=CC=C(C=3C=C(OCC=4C(=CC=CC=4Cl)Cl)C(N)=NC=3)C=C12 WPEGHYKGSUIDLP-UHFFFAOYSA-N 0.000 description 1
- FCTCLLQOESDDRW-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)methoxy]-5-[3-(diethylaminomethyl)-1h-indol-5-yl]pyridin-2-amine Chemical compound C1=C2C(CN(CC)CC)=CNC2=CC=C1C(C=1)=CN=C(N)C=1OCC1=C(Cl)C=CC=C1Cl FCTCLLQOESDDRW-UHFFFAOYSA-N 0.000 description 1
- OHUHINVWRLEAFC-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-(1h-indol-5-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C3C=CNC3=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl OHUHINVWRLEAFC-UHFFFAOYSA-N 0.000 description 1
- QSNKOEXTIQZXDR-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-(3-pyrrolidin-1-ylphenyl)pyridin-2-amine Chemical compound NC1=NC=C(C=2C=C(C=CC=2)N2CCCC2)C=C1OCC1=C(F)C=CC(F)=C1Cl QSNKOEXTIQZXDR-UHFFFAOYSA-N 0.000 description 1
- YOCWHUARDVODGW-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(N)C(OCC=2C(=C(F)C=CC=2F)Cl)=C1 YOCWHUARDVODGW-UHFFFAOYSA-N 0.000 description 1
- AYBJRGJWGQJPKE-UHFFFAOYSA-N 3-[(2-chloro-3,6-difluorophenyl)methoxy]-5-[3-(diethylaminomethyl)-1h-indol-5-yl]pyrazin-2-amine Chemical compound C1=C2C(CN(CC)CC)=CNC2=CC=C1C(N=1)=CN=C(N)C=1OCC1=C(F)C=CC(F)=C1Cl AYBJRGJWGQJPKE-UHFFFAOYSA-N 0.000 description 1
- WWWADLZQZWXBDS-UHFFFAOYSA-N 3-[(2-chlorophenyl)methoxy]-5-pyridin-2-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2N=CC=CC=2)C=C1OCC1=CC=CC=C1Cl WWWADLZQZWXBDS-UHFFFAOYSA-N 0.000 description 1
- NXEOFHUUCWBDOZ-UHFFFAOYSA-N 3-[(2-chlorophenyl)methoxy]-5-pyridin-3-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=CC=2)C=C1OCC1=CC=CC=C1Cl NXEOFHUUCWBDOZ-UHFFFAOYSA-N 0.000 description 1
- HFQWOSKGRHDGFG-UHFFFAOYSA-N 3-[(4-chlorophenyl)methoxy]-5-pyridin-3-ylpyridin-2-amine Chemical compound NC1=NC=C(C=2C=NC=CC=2)C=C1OCC1=CC=C(Cl)C=C1 HFQWOSKGRHDGFG-UHFFFAOYSA-N 0.000 description 1
- DIICUSHOFRGCHG-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1h-indol-5-yl)pyridin-2-amine Chemical compound C=1C(C=2C=C3C=CNC3=CC=2)=CN=C(N)C=1OC(C)C1=C(Cl)C=CC(F)=C1Cl DIICUSHOFRGCHG-UHFFFAOYSA-N 0.000 description 1
- TZSRKCBFXJZQLQ-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(2,5-dimethylphenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC(C)=CC=C1C TZSRKCBFXJZQLQ-UHFFFAOYSA-N 0.000 description 1
- JHARIMMUWWVLAN-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(4-fluorophenyl)pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(F)C=C1 JHARIMMUWWVLAN-UHFFFAOYSA-N 0.000 description 1
- KKZINYKVBJTECW-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrazin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1OCCN1CCOCC1 KKZINYKVBJTECW-UHFFFAOYSA-N 0.000 description 1
- MSCKWFZVEIWVEY-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(dimethylamino)phenyl]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(N(C)C)C=C1 MSCKWFZVEIWVEY-UHFFFAOYSA-N 0.000 description 1
- IEKMAKBQCRKWLS-UHFFFAOYSA-N 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC=CN=C1N IEKMAKBQCRKWLS-UHFFFAOYSA-N 0.000 description 1
- HRCBXHNJYHKJAX-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NC1CCN(C)CC1 HRCBXHNJYHKJAX-UHFFFAOYSA-N 0.000 description 1
- CROKEKPNVNIYDT-UHFFFAOYSA-N 3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]benzoic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C1=CC=CC(C(O)=O)=C1 CROKEKPNVNIYDT-UHFFFAOYSA-N 0.000 description 1
- KVQZKCTVURXNQW-UHFFFAOYSA-N 3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NC1CCN(C)CC1 KVQZKCTVURXNQW-UHFFFAOYSA-N 0.000 description 1
- IBHGKBMGNRICGM-UHFFFAOYSA-N 3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCCN1CCCC1 IBHGKBMGNRICGM-UHFFFAOYSA-N 0.000 description 1
- MDQVERCYURPZNG-UHFFFAOYSA-N 3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=C(C=CC=2)C(O)=O)C=C1OCC1=C(F)C=CC(F)=C1Cl MDQVERCYURPZNG-UHFFFAOYSA-N 0.000 description 1
- OLPPDIXVDCIGBQ-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)NC1CCN(C)CC1 OLPPDIXVDCIGBQ-UHFFFAOYSA-N 0.000 description 1
- BNGZXIZQLLUCSG-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-n-(3-morpholin-4-ylpropyl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)NCCCN1CCOCC1 BNGZXIZQLLUCSG-UHFFFAOYSA-N 0.000 description 1
- QPOSKUIVYUZYFN-UHFFFAOYSA-N 3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=CC(C(O)=O)=C1 QPOSKUIVYUZYFN-UHFFFAOYSA-N 0.000 description 1
- JJSAEDOMTCNEQL-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCCOC1 JJSAEDOMTCNEQL-UHFFFAOYSA-N 0.000 description 1
- NMDUJEUWNLCXSB-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N(CCC(O)=O)C(C)(C)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 NMDUJEUWNLCXSB-UHFFFAOYSA-N 0.000 description 1
- PDCBVHDMAFCHPK-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxycarbamoyl)cyclobutyl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCC1 PDCBVHDMAFCHPK-UHFFFAOYSA-N 0.000 description 1
- YZIGEYGKVJNXSU-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxolane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOC1 YZIGEYGKVJNXSU-UHFFFAOYSA-N 0.000 description 1
- JNETYVLEGPSOFY-UHFFFAOYSA-N 3-bromopyrrolidine-2,5-dione Chemical compound BrC1CC(=O)NC1=O JNETYVLEGPSOFY-UHFFFAOYSA-N 0.000 description 1
- QBPDSKPWYWIHGA-UHFFFAOYSA-N 3-hydroxy-2-nitropyridine Chemical compound OC1=CC=CN=C1[N+]([O-])=O QBPDSKPWYWIHGA-UHFFFAOYSA-N 0.000 description 1
- RPQADWBEACHUFT-UHFFFAOYSA-N 3-phenylmethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(N)C(OCC=2C=CC=CC=2)=C1 RPQADWBEACHUFT-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- JTWNSPXBOBDYBD-UHFFFAOYSA-N 4-(3-amino-3-methylbut-1-ynyl)-2-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]aniline Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC1=CC(C#CC(C)(C)N)=CC=C1N JTWNSPXBOBDYBD-UHFFFAOYSA-N 0.000 description 1
- IYDKBQIEOBXLTP-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C(O)=O)C=C1 IYDKBQIEOBXLTP-UHFFFAOYSA-N 0.000 description 1
- QPPKQHCOWKQUMH-UHFFFAOYSA-N 4-(6-amino-5-phenylmethoxypyridin-3-yl)benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=CC=C1 QPPKQHCOWKQUMH-UHFFFAOYSA-N 0.000 description 1
- NASPVRZCKOAKLC-UHFFFAOYSA-N 4-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=C1)=CC=C1C(=O)NCCCN1CCCC1 NASPVRZCKOAKLC-UHFFFAOYSA-N 0.000 description 1
- URVNYTDEWPOUOS-UHFFFAOYSA-N 4-[6-amino-5-[(2,4-dichlorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=C(Cl)C=C1Cl URVNYTDEWPOUOS-UHFFFAOYSA-N 0.000 description 1
- RIEMQVWWTWQXMA-UHFFFAOYSA-N 4-[6-amino-5-[(2-chloro-6-fluorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=C(F)C=CC=C1Cl RIEMQVWWTWQXMA-UHFFFAOYSA-N 0.000 description 1
- SUWGBKLTGXAPTB-UHFFFAOYSA-N 4-[6-amino-5-[(2-chlorophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=CC=C1Cl SUWGBKLTGXAPTB-UHFFFAOYSA-N 0.000 description 1
- VNAIVZYZFXOZBG-UHFFFAOYSA-N 4-[6-amino-5-[(2-cyanophenyl)methoxy]pyridin-3-yl]benzoic acid Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(O)=O)C=C1OCC1=CC=CC=C1C#N VNAIVZYZFXOZBG-UHFFFAOYSA-N 0.000 description 1
- DWRSFLPJFKITBF-UHFFFAOYSA-N 4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)NCCN1CCCC1 DWRSFLPJFKITBF-UHFFFAOYSA-N 0.000 description 1
- KVUQQKAJQLPTGP-UHFFFAOYSA-N 4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-n-(3-pyrrolidin-1-ylpropyl)benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)NCCCN1CCCC1 KVUQQKAJQLPTGP-UHFFFAOYSA-N 0.000 description 1
- WBQISGWTCROOEI-UHFFFAOYSA-N 4-[6-amino-5-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyridin-3-yl]benzoic acid Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C1=CC=C(C(O)=O)C=C1 WBQISGWTCROOEI-UHFFFAOYSA-N 0.000 description 1
- CYZMUIMLRBJSRO-UHFFFAOYSA-N 4-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 CYZMUIMLRBJSRO-UHFFFAOYSA-N 0.000 description 1
- ZBRHTUMWSDPCMI-UHFFFAOYSA-N 4-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 ZBRHTUMWSDPCMI-UHFFFAOYSA-N 0.000 description 1
- ZUQOBHTUMCEQBG-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 ZUQOBHTUMCEQBG-UHFFFAOYSA-N 0.000 description 1
- BVXHEFWTMMZHDG-UHFFFAOYSA-N 4-nitropyridin-3-ol Chemical compound OC1=CN=CC=C1[N+]([O-])=O BVXHEFWTMMZHDG-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- HHRVQPSCNMUYDE-UHFFFAOYSA-N 5-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]-n-(2-pyrrolidin-1-ylethyl)-1h-indole-2-carboxamide Chemical compound NC1=NC=C(C=2C=C3C=C(NC3=CC=2)C(=O)NCCN2CCCC2)C=C1OCC1=C(Cl)C=CC=C1Cl HHRVQPSCNMUYDE-UHFFFAOYSA-N 0.000 description 1
- YFLDRXOVUCGQEY-UHFFFAOYSA-N 5-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]-n-(1-methylpiperidin-4-yl)thiophene-2-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)S1 YFLDRXOVUCGQEY-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- MQISUXVEATUEPL-UHFFFAOYSA-N 5-bromo-3-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1OCC1=C(F)C=CC(F)=C1Cl MQISUXVEATUEPL-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- RUYPWGCRJXBBCO-UHFFFAOYSA-N 6-amino-5-phenylmethoxypyridine-3-carboxylic acid Chemical compound NC1=NC=C(C(O)=O)C=C1OCC1=CC=CC=C1 RUYPWGCRJXBBCO-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100236399 Arabidopsis thaliana MAPKKK20 gene Proteins 0.000 description 1
- 241000566146 Asio Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 102100032306 Aurora kinase B Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FPEOWPDGANOZMX-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NCCC1=C(C=C(C=C1Cl)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N)Cl Chemical compound C(C1=CC=CC=C1)(=O)NCCC1=C(C=C(C=C1Cl)C(C)OC=1C(=NC=C(C1)C1=CC=C(C=C1)C(=O)N1CCC(CC1)N1CCCC1)N)Cl FPEOWPDGANOZMX-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- AANFEHRCYPKPDI-UHFFFAOYSA-N ClC1=C(COC=2C=NC=C(C2)C=2C=C3C(=CNC3=CC2)C=2CCN(CC2)C)C(=CC=C1)Cl Chemical compound ClC1=C(COC=2C=NC=C(C2)C=2C=C3C(=CNC3=CC2)C=2CCN(CC2)C)C(=CC=C1)Cl AANFEHRCYPKPDI-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VHHGUBHZBLPTKL-UHFFFAOYSA-N Cp-471358 Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 VHHGUBHZBLPTKL-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
- 235000019227 E-number Nutrition 0.000 description 1
- 239000004243 E-number Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101000841259 Homo sapiens Endothelin-converting enzyme 1 Proteins 0.000 description 1
- 101000938351 Homo sapiens Ephrin type-A receptor 3 Proteins 0.000 description 1
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000873676 Homo sapiens Secretogranin-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101000967022 Locusta migratoria Endothelin-converting enzyme homolog Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- IAPXZFBICYPBDI-UHFFFAOYSA-N NC1=C(C=C(C=N1)C=1C=C2C(=CNC2=CC1)CN1CCNCC1)OCC1=C(C(=CC=C1F)F)Cl Chemical compound NC1=C(C=C(C=N1)C=1C=C2C(=CNC2=CC1)CN1CCNCC1)OCC1=C(C(=CC=C1F)F)Cl IAPXZFBICYPBDI-UHFFFAOYSA-N 0.000 description 1
- YAPQRZRSJVDLGL-UHFFFAOYSA-N NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 Chemical compound NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 YAPQRZRSJVDLGL-UHFFFAOYSA-N 0.000 description 1
- JQPLTYHSBLVAOD-UHFFFAOYSA-N NC=1N=CC(=NC=1OCC1=C(C(=CC=C1F)F)Cl)C1=CC=C(C=C1)NS(=O)(=O)CC Chemical compound NC=1N=CC(=NC=1OCC1=C(C(=CC=C1F)F)Cl)C1=CC=C(C=C1)NS(=O)(=O)CC JQPLTYHSBLVAOD-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 101100178269 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hob1 gene Proteins 0.000 description 1
- 102100035835 Secretogranin-2 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100037580 Sesquipedalian-1 Human genes 0.000 description 1
- 101710169844 Sesquipedalian-1 Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 102000005737 Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 1
- 108010045627 Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- QSUIOALMASVEGK-UHFFFAOYSA-N [3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 QSUIOALMASVEGK-UHFFFAOYSA-N 0.000 description 1
- BARVMPVCTIISNS-UHFFFAOYSA-N [3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)N1CCN(C)CC1 BARVMPVCTIISNS-UHFFFAOYSA-N 0.000 description 1
- HRKVUBFJPHLKAG-UHFFFAOYSA-N [4-(6-amino-5-phenylmethoxypyridin-3-yl)phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=CC=C1 HRKVUBFJPHLKAG-UHFFFAOYSA-N 0.000 description 1
- VPTPCJYCHCZXEI-UHFFFAOYSA-N [4-[5-amino-6-[(2-chloro-3,6-difluorophenyl)methoxy]pyrazin-2-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2N=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 VPTPCJYCHCZXEI-UHFFFAOYSA-N 0.000 description 1
- ZOJKTIWXQGFYJX-UHFFFAOYSA-N [4-[5-amino-6-[[3-fluoro-2-(trifluoromethyl)phenyl]methoxy]pyrazin-2-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2N=C(OCC=3C(=C(F)C=CC=3)C(F)(F)F)C(N)=NC=2)C=C1 ZOJKTIWXQGFYJX-UHFFFAOYSA-N 0.000 description 1
- QWSDYGXUBMHYCQ-UHFFFAOYSA-N [4-[6-amino-5-[(2,4,6-trifluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=C(F)C=C(F)C=C1F QWSDYGXUBMHYCQ-UHFFFAOYSA-N 0.000 description 1
- BQLIPHAYBQJJEO-UHFFFAOYSA-N [4-[6-amino-5-[(2,4,6-trimethylphenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound CC1=CC(C)=CC(C)=C1COC1=CC(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)=CN=C1N BQLIPHAYBQJJEO-UHFFFAOYSA-N 0.000 description 1
- JBRREMBHYRJXKI-UHFFFAOYSA-N [4-[6-amino-5-[(2,4-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC(Cl)=CC=3)Cl)C(N)=NC=2)C=C1 JBRREMBHYRJXKI-UHFFFAOYSA-N 0.000 description 1
- PITBRTYDMRSIJP-UHFFFAOYSA-N [4-[6-amino-5-[(2,4-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=C(Cl)C=C1Cl PITBRTYDMRSIJP-UHFFFAOYSA-N 0.000 description 1
- BWKUUUWGIUIIOC-UHFFFAOYSA-N [4-[6-amino-5-[(2,6-dichlorophenyl)methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3Cl)Cl)C(N)=NC=2)C=C1 BWKUUUWGIUIIOC-UHFFFAOYSA-N 0.000 description 1
- ALFCHUSVMHAUCR-UHFFFAOYSA-N [4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)C=C1 ALFCHUSVMHAUCR-UHFFFAOYSA-N 0.000 description 1
- ZLZNVGRADVBRLM-UHFFFAOYSA-N [4-[6-amino-5-[(2-chloro-6-fluorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3F)Cl)C(N)=NC=2)C=C1 ZLZNVGRADVBRLM-UHFFFAOYSA-N 0.000 description 1
- VVTLOTJELICEQR-UHFFFAOYSA-N [4-[6-amino-5-[(2-chlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)Cl)C(N)=NC=2)C=C1 VVTLOTJELICEQR-UHFFFAOYSA-N 0.000 description 1
- SWJCPVPNVFOEIB-UHFFFAOYSA-N [4-[6-amino-5-[(2-chlorophenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound NC1=NC=C(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)C=C1OCC1=CC=CC=C1Cl SWJCPVPNVFOEIB-UHFFFAOYSA-N 0.000 description 1
- NRHDODUAMRGLIM-UHFFFAOYSA-N [4-[6-amino-5-[(2-methylphenyl)methoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound C1C(C)NC(C)CN1C(=O)C1=CC=C(C=2C=C(OCC=3C(=CC=CC=3)C)C(N)=NC=2)C=C1 NRHDODUAMRGLIM-UHFFFAOYSA-N 0.000 description 1
- DOAOMVUAMWDVSU-UHFFFAOYSA-N [4-[6-amino-5-[(2-methylphenyl)methoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound CC1=CC=CC=C1COC1=CC(C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)=CN=C1N DOAOMVUAMWDVSU-UHFFFAOYSA-N 0.000 description 1
- DTGMQUFOTAONOG-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,4,5-trifluorophenyl)propoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound C=1C(F)=C(F)C=C(F)C=1C(CC)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 DTGMQUFOTAONOG-UHFFFAOYSA-N 0.000 description 1
- WBPXLPQIBWXLEL-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,4,6-trimethylphenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound CC=1C=C(C)C=C(C)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 WBPXLPQIBWXLEL-UHFFFAOYSA-N 0.000 description 1
- SFJLYEILLBTPBF-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-aminopiperidin-1-yl)methanone Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CCC(N)CC1 SFJLYEILLBTPBF-UHFFFAOYSA-N 0.000 description 1
- RYNWHMVYHXUHGE-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-ethylpiperazin-1-yl)methanone Chemical compound C1CN(CC)CCN1C(=O)C1=CC=C(C=2C=C(OC(C)C=3C(=C(F)C=CC=3Cl)Cl)C(N)=NC=2)C=C1 RYNWHMVYHXUHGE-UHFFFAOYSA-N 0.000 description 1
- WSANBMQPGMLNPV-UHFFFAOYSA-N [4-[6-amino-5-[1-(2,6-dichlorophenyl)propoxy]pyridin-3-yl]phenyl]-(3,5-dimethylpiperazin-1-yl)methanone Chemical compound ClC=1C=CC=C(Cl)C=1C(CC)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N1CC(C)NC(C)C1 WSANBMQPGMLNPV-UHFFFAOYSA-N 0.000 description 1
- IAXQEKGFSAOTRP-UHFFFAOYSA-N [4-[6-amino-5-[1-(2-chloro-6-fluorophenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound FC=1C=CC=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 IAXQEKGFSAOTRP-UHFFFAOYSA-N 0.000 description 1
- SBOQWEGYCBYIFA-UHFFFAOYSA-N [4-[6-amino-5-[1-(6-chloro-2-fluoro-3-methylphenyl)ethoxy]pyridin-3-yl]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound ClC=1C=CC(C)=C(F)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 SBOQWEGYCBYIFA-UHFFFAOYSA-N 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000021592 benign granular cell tumor Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PEYNLAQGUNUQLY-UHFFFAOYSA-N chembl333137 Chemical compound C1=CC=C2C(N=NC(=S)N)=C(O)NC2=C1 PEYNLAQGUNUQLY-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000057421 human MET Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- PYFSLJVSCGXYAJ-UHFFFAOYSA-N methyl 2-hydroxy-4-[[3-(2-hydroxyphenyl)phenyl]sulfonylamino]benzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC=CC(C=2C(=CC=CC=2)O)=C1 PYFSLJVSCGXYAJ-UHFFFAOYSA-N 0.000 description 1
- OPJQVCGXKAKKCT-UHFFFAOYSA-N methyl 3-[[2-amino-5-[4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)phenyl]pyridin-3-yl]oxymethyl]benzoate Chemical compound COC(=O)C1=CC=CC(COC=2C(=NC=C(C=2)C=2C=CC(=CC=2)C(=O)N2CCC(CC2)N2CCCC2)N)=C1 OPJQVCGXKAKKCT-UHFFFAOYSA-N 0.000 description 1
- XGMBFMPFJJWCAP-UHFFFAOYSA-N methyl 4-(6-amino-5-phenylmethoxypyridin-3-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(N)C(OCC=2C=CC=CC=2)=C1 XGMBFMPFJJWCAP-UHFFFAOYSA-N 0.000 description 1
- QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 1
- YZLKMLUFQNRLJQ-UHFFFAOYSA-N methyl 4-[6-amino-5-(4-methylphenyl)sulfonyloxypyridin-3-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CN=C(N)C(OS(=O)(=O)C=2C=CC(C)=CC=2)=C1 YZLKMLUFQNRLJQ-UHFFFAOYSA-N 0.000 description 1
- YGDGZDGRCWHDOU-UHFFFAOYSA-N methyl 4-[[5-chloro-4-(2-hydroxyphenyl)thiophen-2-yl]sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=CC(C=2C(=CC=CC=2)O)=C(Cl)S1 YGDGZDGRCWHDOU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000004130 myoblastoma Diseases 0.000 description 1
- XIZKFNYILAFPHD-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-3-[5-amino-6-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyrazin-2-yl]benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCN1CCN(C(C)=O)CC1 XIZKFNYILAFPHD-UHFFFAOYSA-N 0.000 description 1
- VNOYKMOMHGRJKG-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-3-[5-amino-6-[1-(2-chloro-3,6-difluorophenyl)ethoxy]pyrazin-2-yl]benzamide Chemical compound FC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=NC=1C(C=1)=CC=CC=1C(=O)NCCN1CCN(C(C)=O)CC1 VNOYKMOMHGRJKG-UHFFFAOYSA-N 0.000 description 1
- ASPWPTGBBNMCPW-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-3-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=1)=CC=CC=1C(=O)NCCN1CCN(C(C)=O)CC1 ASPWPTGBBNMCPW-UHFFFAOYSA-N 0.000 description 1
- HDRGMRMNNLWZDJ-UHFFFAOYSA-N n-[2-(4-acetylpiperazin-1-yl)ethyl]-4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]benzamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C(C=C1)=CC=C1C(=O)NCCN1CCN(C(C)=O)CC1 HDRGMRMNNLWZDJ-UHFFFAOYSA-N 0.000 description 1
- LBMJAFKZXMOCPB-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound CN(C)CCS(=O)(=O)NC1=CC=CC(C=2C=C(OCC=3C(=C(F)C=CC=3F)Cl)C(N)=NC=2)=C1 LBMJAFKZXMOCPB-UHFFFAOYSA-N 0.000 description 1
- ZHGNEFBCFWMVMY-UHFFFAOYSA-N n-[3-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-morpholin-4-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=C(NS(=O)(=O)CCN3CCOCC3)C=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl ZHGNEFBCFWMVMY-UHFFFAOYSA-N 0.000 description 1
- PYJBWQOVLPMCGJ-UHFFFAOYSA-N n-[4-[6-amino-5-[(2-chloro-3,6-difluorophenyl)methoxy]pyridin-3-yl]phenyl]-2-piperidin-1-ylethanesulfonamide Chemical compound NC1=NC=C(C=2C=CC(NS(=O)(=O)CCN3CCCCC3)=CC=2)C=C1OCC1=C(F)C=CC(F)=C1Cl PYJBWQOVLPMCGJ-UHFFFAOYSA-N 0.000 description 1
- IQEPSMWHMPUHRR-UHFFFAOYSA-N n-[4-[6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl]-2-methylbut-3-yn-2-yl]-4-pyrrolidin-1-ylpiperidine-1-carboxamide Chemical compound ClC=1C=CC(F)=C(Cl)C=1C(C)OC(C(=NC=1)N)=CC=1C#CC(C)(C)NC(=O)N(CC1)CCC1N1CCCC1 IQEPSMWHMPUHRR-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- OVLXOTUWFLHWQT-UHFFFAOYSA-N oxazolo[4,5-b]pyridin-2(3H)-one Chemical compound C1=CC=C2OC(=O)NC2=N1 OVLXOTUWFLHWQT-UHFFFAOYSA-N 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000003913 parathyroid carcinoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- IQRVRJMJNKERNO-UHFFFAOYSA-N prop-2-ynylcarbamic acid Chemical compound OC(=O)NCC#C IQRVRJMJNKERNO-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical class [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44958803P | 2003-02-26 | 2003-02-26 | |
| US54022904P | 2004-01-29 | 2004-01-29 | |
| PCT/US2004/005495 WO2004076412A2 (en) | 2003-02-26 | 2004-02-26 | Aminoheteroaryl compounds as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200501236A1 EA200501236A1 (ru) | 2006-04-28 |
| EA010727B1 true EA010727B1 (ru) | 2008-10-30 |
Family
ID=32930516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200501236A EA010727B1 (ru) | 2003-02-26 | 2004-02-26 | Аминогетероарильные соединения в качестве ингибиторов протеинкиназ |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7230098B2 (enExample) |
| EP (2) | EP1603570B9 (enExample) |
| JP (1) | JP4695588B2 (enExample) |
| KR (1) | KR101106905B1 (enExample) |
| CN (1) | CN103265477B (enExample) |
| AP (1) | AP2114A (enExample) |
| AU (1) | AU2004215428B2 (enExample) |
| BR (1) | BRPI0407827B8 (enExample) |
| CA (1) | CA2517256C (enExample) |
| CY (2) | CY1113837T1 (enExample) |
| DK (2) | DK1603570T5 (enExample) |
| EA (1) | EA010727B1 (enExample) |
| EC (1) | ECSP055988A (enExample) |
| ES (2) | ES2401330T3 (enExample) |
| GE (1) | GEP20084341B (enExample) |
| HR (1) | HRP20050714B1 (enExample) |
| IL (1) | IL170291A (enExample) |
| IS (1) | IS2910B (enExample) |
| MA (1) | MA27713A1 (enExample) |
| ME (1) | MEP52808A (enExample) |
| MX (1) | MXPA05009063A (enExample) |
| NO (1) | NO332188B1 (enExample) |
| NZ (1) | NZ541861A (enExample) |
| OA (1) | OA13151A (enExample) |
| PL (1) | PL216368B1 (enExample) |
| PT (2) | PT2476667E (enExample) |
| RS (1) | RS53118B (enExample) |
| TN (1) | TNSN05208A1 (enExample) |
| WO (1) | WO2004076412A2 (enExample) |
Families Citing this family (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1603570T5 (da) * | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| CA2556025A1 (en) * | 2004-02-23 | 2005-09-09 | Sugen, Inc. | Method of treating abnormal cell growth using c-met and m-tor inhibitors |
| EP1719763A4 (en) * | 2004-02-27 | 2008-01-09 | Eisai R&D Man Co Ltd | NEW PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) |
| JP2007531757A (ja) * | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | 抗癌剤としての置換チオフェン誘導体 |
| MXPA06011167A (es) * | 2004-04-01 | 2007-01-25 | Eli Lilli And Company | Agentes del receptor h3 de histamina, preparacion y usos terapeuticos. |
| US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| BRPI0514553A (pt) * | 2004-08-23 | 2008-06-17 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo |
| MX2007001986A (es) * | 2004-08-26 | 2007-05-10 | Pfizer | Compuestos de aminoheteroarilo como inhibidores de proteina quinasa. |
| KR20080072105A (ko) * | 2004-08-26 | 2008-08-05 | 화이자 인코포레이티드 | 단백질 티로신 키나제 저해제 중간체의 제조를 위한거울상이성질선택적 생물학적 전환 |
| CA2577937C (en) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| JP4242911B2 (ja) | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| JP2008535790A (ja) * | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュインモジュレーターであるn−フェニルベンズアミド誘導体 |
| BRPI0611439A2 (pt) * | 2005-05-13 | 2010-09-08 | Lexicon Pharmaceuticals Inc | compostos multicìclicos e métodos para uso dos mesmos |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| AU2006278504B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007023768A1 (ja) | 2005-08-24 | 2007-03-01 | Eisai R & D Management Co., Ltd. | 新規ピリジン誘導体およびピリミジン誘導体(3) |
| US7825137B2 (en) * | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
| DK1963302T3 (da) * | 2005-12-05 | 2013-04-02 | Pfizer Prod Inc | Polymorfer af en C-MET/HGFR-inhibitor |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
| WO2007111904A2 (en) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| ES2561406T3 (es) | 2006-04-14 | 2016-02-26 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| ES2375284T3 (es) | 2006-08-23 | 2012-02-28 | Eisai R&D Management Co., Ltd. | Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma. |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| JP5512274B2 (ja) | 2006-10-23 | 2014-06-04 | セファロン、インク. | ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体 |
| GB0621607D0 (en) * | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
| GEP20125658B (en) | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| ES2396160T3 (es) | 2006-12-14 | 2013-02-19 | Bayer Intellectual Property Gmbh | Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa |
| WO2008087736A1 (ja) * | 2007-01-19 | 2008-07-24 | Ube Industries, Ltd. | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
| US8551995B2 (en) * | 2007-01-19 | 2013-10-08 | Xcovery Holding Company, Llc | Kinase inhibitor compounds |
| EP2851091B1 (en) | 2007-04-13 | 2017-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to ERBB therapeutics |
| CA2951295C (en) * | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| US8263585B2 (en) | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
| CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| EP2173722B1 (en) * | 2007-07-26 | 2012-08-29 | Novartis AG | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
| CN101855342B (zh) | 2007-09-13 | 2013-07-10 | 科德克希思公司 | 用于还原苯乙酮的酮还原酶多肽 |
| EP2215084B1 (en) * | 2007-10-23 | 2016-09-28 | Allergan, Inc. | Therapeutic substituted lactams |
| AU2008319267A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| EP2217606A1 (en) * | 2007-11-08 | 2010-08-18 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| WO2009073224A1 (en) * | 2007-12-07 | 2009-06-11 | Ambit Biosciences Corp. | Methods of treating certain diseases using pyrimidine derivatives |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| JPWO2009096198A1 (ja) * | 2008-02-01 | 2011-05-26 | 一般社団法人ファルマIp | 新規ビアリール誘導体 |
| JP2011511005A (ja) * | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 2−アミノピリジン系キナーゼ阻害薬 |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| EP2248810A4 (en) * | 2008-02-18 | 2011-05-25 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE |
| WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| FR2928923B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928924B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| FR2928922B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| CN103936743B (zh) | 2008-05-21 | 2018-04-24 | 因西特控股公司 | 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法 |
| PL2303018T3 (pl) | 2008-06-19 | 2016-06-30 | Xcovery Holdings Inc | Podstawione związki pirydazynokarboksyamidowe jako związki będące inhibitorami kinazy |
| JP2012501188A (ja) * | 2008-08-29 | 2012-01-19 | ジェネンテック, インコーポレイテッド | Vegf非依存性腫瘍についての診断薬および治療 |
| WO2010046780A2 (en) * | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン |
| EP2375904B1 (en) * | 2008-12-09 | 2014-05-28 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| AU2009327357C1 (en) | 2008-12-19 | 2017-02-02 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of ATR kinase |
| JP2012102018A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | アミド化合物 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
| EA025304B1 (ru) | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
| WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| WO2011143423A2 (en) * | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| JP2013526570A (ja) | 2010-05-14 | 2013-06-24 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 縮合二環式キナーゼ阻害剤 |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| WO2012048259A2 (en) | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds |
| PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
| GB201021103D0 (en) | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| CN103491815B (zh) | 2011-02-11 | 2016-01-20 | 巴特马克有限公司 | 吸入器组件 |
| CA2826892A1 (en) * | 2011-02-24 | 2012-08-30 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2012152741A1 (de) | 2011-05-10 | 2012-11-15 | Bayer Intellectual Property Gmbh | Bicyclische (thio)carbonylamidine |
| US20140088114A1 (en) | 2011-05-16 | 2014-03-27 | OSI Pharmaceuticals ,LLC | Fused bicyclic kinase inhibitors |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
| US9226923B2 (en) * | 2011-07-27 | 2016-01-05 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
| MX2014001354A (es) | 2011-08-02 | 2014-10-14 | Pfizer | Crizotinib para uso en el tratamiento de cancer. |
| RS59337B1 (sr) | 2011-09-30 | 2019-10-31 | Vertex Pharma | Postupak za izradu jedinjenja, korisnih kao inhibitori atr kinaze |
| SG11201401095YA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| EP2822953B9 (en) | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
| AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
| ES2654670T3 (es) | 2012-04-05 | 2018-02-14 | Vertex Pharmaceuticals Incorporated | Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| CN103387535B (zh) * | 2012-05-10 | 2016-06-01 | 广东东阳光药业有限公司 | 取代的炔基吡啶化合物及其使用方法和用途 |
| WO2013177092A1 (en) * | 2012-05-23 | 2013-11-28 | Sunshine Lake Pharma Co., Ltd. | Substituted alkynyl pyridine compounds and methods of use |
| GB201211310D0 (en) * | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN104603620B (zh) | 2012-09-24 | 2018-02-23 | 文塔纳医疗系统公司 | 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法 |
| WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| US20150299170A1 (en) * | 2012-11-21 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds |
| PT4190786T (pt) | 2012-12-07 | 2025-05-29 | Vertex Pharma | Compostos úteis como inibidores da quinase atr |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
| US9708295B2 (en) * | 2013-02-02 | 2017-07-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Substituted 2-aminopyridine protein kinase inhibitor |
| EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
| SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| WO2015034729A1 (en) * | 2013-09-05 | 2015-03-12 | Calitor Sciences, Llc | Substituted pyridine compounds and methods of use |
| US20160214961A1 (en) * | 2013-09-10 | 2016-07-28 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| ES2675355T3 (es) | 2013-09-30 | 2018-07-10 | Korea Research Institute Of Chemical Technology | Derivados de triazolopirazina como inhibidores de tirosina cinasa |
| US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| EP3083583B1 (en) | 2013-12-20 | 2020-11-18 | Sagimet Biosciences Inc. | Heterocyclic modulators of lipid synthesis and combinations thereof |
| CN103755627B (zh) * | 2014-01-09 | 2016-02-17 | 定陶县友帮化工有限公司 | 2-氨基-3-羟基-5-氯吡啶的合成方法 |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| WO2015167825A1 (en) | 2014-04-29 | 2015-11-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| WO2015172747A1 (en) * | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| KR102575125B1 (ko) | 2014-06-05 | 2023-09-07 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태 |
| RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
| WO2016019909A1 (zh) * | 2014-08-07 | 2016-02-11 | 江苏豪森药业股份有限公司 | 一种抗癌化合物的新晶型及其制备方法和用途 |
| WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| IL302218B2 (en) | 2014-08-28 | 2024-10-01 | Eisai R&D Man Co Ltd | Methods for manufacturing high-purity lenvatinib and its derivatives |
| KR102569226B1 (ko) * | 2014-10-13 | 2023-08-22 | 아트린 파마슈티컬스 엘엘씨 | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| ES2928502T3 (es) | 2014-11-07 | 2022-11-18 | Univ Michigan Regents | Inhibidores de la transcripción génica mediada por el factor de transcripción relacionado con la miocardina y el factor de respuesta sérica (MRTF/SRF) y métodos para el uso de los mismos |
| US10085979B2 (en) | 2014-12-02 | 2018-10-02 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| US20180000771A1 (en) | 2015-01-13 | 2018-01-04 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| KR20180011843A (ko) | 2015-06-11 | 2018-02-02 | 바실리어 파마슈티카 인터내셔널 리미티드 | 유출-펌프 억제제 및 이의 치료적 용도 |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| US10405627B2 (en) * | 2015-07-14 | 2019-09-10 | Michael Charles Boland, III | Luggage with fold out table |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
| WO2017161004A1 (en) | 2016-03-15 | 2017-09-21 | University Of South Florida | PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS |
| WO2017180723A1 (en) | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| WO2017201585A1 (en) * | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
| CN106866627B (zh) * | 2017-01-24 | 2021-09-14 | 南方医科大学 | 3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用 |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| AU2018302178A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| JP7203083B2 (ja) | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
| EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
| CN107794282B (zh) * | 2017-11-20 | 2020-12-25 | 浙江工业大学 | 一种克唑替尼手性中间体的制备方法及菌株 |
| WO2019154665A1 (en) * | 2018-02-07 | 2019-08-15 | Basf Se | New pyridine carboxamides |
| ES2920702T3 (es) * | 2018-03-15 | 2022-08-08 | Fujian Haixi Pharmaceuticals Co Ltd | Compuestos de heteroarilo como inhibidores de cinasas |
| CN110372664A (zh) * | 2018-04-13 | 2019-10-25 | 华东理工大学 | 选择性jak2抑制剂及其应用 |
| WO2019206049A1 (en) * | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
| CN110396087A (zh) | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
| CN108947895B (zh) * | 2018-08-22 | 2021-09-24 | 肇庆中彩机电技术研发有限公司 | 一种抗癌活性的化合物 |
| CA3126704A1 (en) * | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| KR20210116550A (ko) | 2019-01-18 | 2021-09-27 | 누베이션 바이오 인크. | 아데노신 길항제로서의 헤테로시클릭 화합물 |
| CA3133797A1 (en) | 2019-03-20 | 2020-09-24 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto |
| CN112533927B (zh) | 2019-05-14 | 2025-06-17 | 苏州韬略生物科技股份有限公司 | 可用作激酶抑制剂的被取代的大环 |
| KR102426921B1 (ko) | 2019-09-24 | 2022-07-29 | 주식회사 이노보테라퓨틱스 | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
| KR102344185B1 (ko) * | 2020-02-26 | 2021-12-27 | 계명대학교 산학협력단 | 신규한 Pim 키나아제 억제제 및 이의 용도 |
| CN113493437B (zh) * | 2020-04-03 | 2022-07-26 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法和用途 |
| WO2021196655A1 (zh) * | 2020-04-03 | 2021-10-07 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法与用途 |
| EP4433445A1 (en) * | 2021-11-15 | 2024-09-25 | The Broad Institute, Inc. | Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections |
| JPWO2024009921A1 (enExample) | 2022-07-04 | 2024-01-11 | ||
| CA3262258A1 (en) | 2022-08-30 | 2025-06-12 | Chugai Pharmaceutical Co Ltd | Combination drug |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000666A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | 5-ht receptor ligands and uses thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| EP0654024A1 (en) | 1992-08-06 | 1995-05-24 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5521190A (en) * | 1993-05-27 | 1996-05-28 | Fmc Corporation | Insecticidal pterdines and 8-deazapteridines |
| JPH07109260A (ja) | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | 5−アミノ−2−ニトロピリジン誘導体及び2,5−ジアミノ−3−ヒドロキシピリジン誘導体の製造方法 |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| DE69718472T2 (de) | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd., Greenford | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| KR20000067904A (ko) | 1996-07-18 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 매트릭스 메탈로프로테아제의 포스피네이트계 억제제 |
| BR9711223A (pt) | 1996-08-23 | 1999-08-17 | Pfizer | Derivados de cido arilsulfonilamino-hidrox mico |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
| IL131042A0 (en) | 1997-02-03 | 2001-01-28 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives |
| BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
| KR20000070923A (ko) | 1997-02-11 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐 하이드록삼산 유도체 |
| SE9700661D0 (sv) * | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| CA2314156C (en) | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US20010002396A1 (en) * | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
| ID29584A (id) | 1999-02-11 | 2001-09-06 | Pfizer Prod Inc | Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| EP1206265B1 (en) * | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| NZ520484A (en) | 2000-02-16 | 2005-03-24 | Neurogen Corp | Substituted arylpyrazines that are modulators of CRF (corticotropin releasing factor) receptor and methods of treatment using them |
| KR100997596B1 (ko) | 2000-07-07 | 2010-11-30 | 파라테크 파마슈티컬스, 인크. | 7-치환 테트라사이클린 화합물 |
| PT1330452E (pt) * | 2000-09-20 | 2009-01-22 | Ortho Mcneil Pharm Inc | Derivados de pirazina como moduladores de tirosina-cinases |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| AU2002256615B2 (en) * | 2001-02-12 | 2007-09-13 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| ATE447561T1 (de) | 2001-11-21 | 2009-11-15 | Pharmacia & Upjohn Co Llc | Substituierte aryl 1,4-pyrazin derivate |
| DK1603570T5 (da) * | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| JP4242911B2 (ja) * | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
| CA2577937C (en) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| US9672526B2 (en) | 2012-03-13 | 2017-06-06 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2004
- 2004-02-26 DK DK04715001.6T patent/DK1603570T5/da active
- 2004-02-26 OA OA1200500243A patent/OA13151A/en unknown
- 2004-02-26 JP JP2006503845A patent/JP4695588B2/ja not_active Expired - Lifetime
- 2004-02-26 ME MEP-528/08A patent/MEP52808A/xx unknown
- 2004-02-26 RS YU20050708A patent/RS53118B/sr unknown
- 2004-02-26 EP EP04715001.6A patent/EP1603570B9/en not_active Expired - Lifetime
- 2004-02-26 PT PT121638555T patent/PT2476667E/pt unknown
- 2004-02-26 KR KR1020057015999A patent/KR101106905B1/ko not_active Expired - Lifetime
- 2004-02-26 EP EP12163855.5A patent/EP2476667B1/en not_active Expired - Lifetime
- 2004-02-26 DK DK12163855.5T patent/DK2476667T3/da active
- 2004-02-26 HR HRP20050714AA patent/HRP20050714B1/hr not_active IP Right Cessation
- 2004-02-26 AU AU2004215428A patent/AU2004215428B2/en active Active
- 2004-02-26 BR BRPI0407827A patent/BRPI0407827B8/pt not_active IP Right Cessation
- 2004-02-26 NZ NZ541861A patent/NZ541861A/en not_active IP Right Cessation
- 2004-02-26 AP AP2005003383A patent/AP2114A/xx active
- 2004-02-26 CA CA2517256A patent/CA2517256C/en not_active Expired - Lifetime
- 2004-02-26 PL PL378759A patent/PL216368B1/pl unknown
- 2004-02-26 PT PT47150016T patent/PT1603570E/pt unknown
- 2004-02-26 MX MXPA05009063A patent/MXPA05009063A/es active IP Right Grant
- 2004-02-26 CN CN201310167961.7A patent/CN103265477B/zh not_active Expired - Lifetime
- 2004-02-26 GE GEAP20048993A patent/GEP20084341B/en unknown
- 2004-02-26 ES ES04715001T patent/ES2401330T3/es not_active Expired - Lifetime
- 2004-02-26 ES ES12163855.5T patent/ES2502490T3/es not_active Expired - Lifetime
- 2004-02-26 WO PCT/US2004/005495 patent/WO2004076412A2/en not_active Ceased
- 2004-02-26 EA EA200501236A patent/EA010727B1/ru active Protection Beyond IP Right Term
- 2004-02-26 US US10/786,610 patent/US7230098B2/en not_active Expired - Lifetime
-
2005
- 2005-08-15 IL IL170291A patent/IL170291A/en active Protection Beyond IP Right Term
- 2005-08-18 IS IS7990A patent/IS2910B/is unknown
- 2005-08-26 MA MA28457A patent/MA27713A1/fr unknown
- 2005-08-26 EC EC2005005988A patent/ECSP055988A/es unknown
- 2005-08-26 TN TNP2005000208A patent/TNSN05208A1/fr unknown
- 2005-09-01 NO NO20054080A patent/NO332188B1/no unknown
-
2006
- 2006-11-14 US US11/598,765 patent/US8106197B2/en active Active
-
2013
- 2013-03-19 CY CY20131100229T patent/CY1113837T1/el unknown
-
2014
- 2014-08-20 CY CY20141100664T patent/CY1115472T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000666A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | 5-ht receptor ligands and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA010727B1 (ru) | Аминогетероарильные соединения в качестве ингибиторов протеинкиназ | |
| US20230076820A1 (en) | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | |
| CN110183422B (zh) | 核转运调节剂及其用途 | |
| KR102534962B1 (ko) | 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물 | |
| JP5764555B2 (ja) | 治療組成物および関連する使用方法 | |
| JP5642963B2 (ja) | ピリジノニルpdk1阻害剤 | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| TW202144345A (zh) | Kras突變蛋白抑制劑 | |
| TW386991B (en) | Indoloylguanidine derivatives | |
| CN102131389A (zh) | 三唑并吡啶jak抑制剂化合物和方法 | |
| TW201238950A (en) | NAMPT and rock inhibitors | |
| WO2017106818A1 (en) | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists | |
| CN112457306A (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
| KR20230043885A (ko) | 트리시클릭 헤테로사이클 | |
| BR112020017087A2 (pt) | Indazol-3-carboxamidas substituídas 5-heteroarila e preparação e uso das mesmas | |
| NO342001B1 (no) | C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose. | |
| CA2747365A1 (fr) | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo[1,2-b]-pyridazine, leur preparation et leur application en therapeutique | |
| WO2023078451A1 (zh) | 用作cdk7激酶抑制剂的化合物及其应用 | |
| CN106459041A (zh) | 嘧啶并[4,5‑b]喹啉‑4,5(3H,10H)‑二酮衍生物 | |
| CA2743560A1 (fr) | Derives de 6-cycloamino-3-(1h-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]-pyridazine, leur preparation et leur application en therapeutique | |
| WO2021004482A1 (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
| EP4428121A1 (en) | Modulators of sortilin activity | |
| KR102344185B1 (ko) | 신규한 Pim 키나아제 억제제 및 이의 용도 | |
| RU2787994C2 (ru) | Замещенные соединения пиразола и способы их применения для лечения гиперпролиферативных заболеваний | |
| CN116925070A (zh) | 取代的氮杂稠环化合物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of term of a eurasian patent | ||
| ND4A | Extension of term of a eurasian patent | ||
| ND4A | Extension of term of a eurasian patent | ||
| ND4A | Extension of term of a eurasian patent |